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Title of the Abstract : Prevalence of asymptomatic cardiac and renal damage
in treatment naïve adult patients with Systemic
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Objectives:
To look at the prevalence of asymptomatic cardiac and renal damage in newly
diagnosed treatment naive adult patients with systemic hypertension and to study
the co-relation between inflammatory markers, hsCRP and uric acid, with the
asymptomatic organ damage in hypertensives.
Methods:
The study recruited 98 hypertensives who presented to the medicine OPD and
were willing to participate in the study. The patient data was collected with a
questionnaire and the blood pressure, height, weight and abdominal circumference
were measured in these patients. The blood investigations including fasting glucose,
creatinine, electrolytes and lipid profile were done in these patients. The patients
also underwent electrocardiography and echocardiography with the documentation
of M-Mode values. The albumin creatinine ratio, eGFR and the LV Mass index were
also subsequently calculated in these patients.
Results
The prevalence of microalbuminuria was 31.9% and the prevalence of Left
ventricular Hypertrophy was 29.59% of the study population. The uric and hsCRP
were not related to asymptomatic organ damage when analysed. The hsCRP was
however very significantly related to body mass index (p=0.000) and abdominal
circumference (p=0.003) on bivariate analysis. This association of hsCRP to elevated
body mass index and abdominal circumference might be due to its association with
the metabolic syndrome.
Conclusion
Almost one third of the newly detected hypertensives in the study population
had evidence of asymptomatic cardiac and renal damage. However, the
asymptomatic cardiac and renal damage was not related to elevated inflammatory
markers in these patients. The elevated hsCRP in the study population might be
related to an underlying metabolic syndrome.
Keywords
Microalbuminuria, LV Mass Index, Asymptomatic organ damage, newly detected
hypertension, prevalence of asymptomatic organ damage.
2Introduction
Hypertension, a chronic disorder, is one of the most common non-
communicable diseases of the modern era. The burden of hypertension, according
to the WHO is estimated to be around one sixth of the world population by 2025.
Moreover, most of the affected population will be in the developing countries. The
number of adults with hypertension in the world in 2000 was 927 million of which
the burden in the developing countries is 639 million1. By 2025 the number of
hypertensives in the world is expected to increase upto 1·56 billion1.
Hypertension is the leading cause of stroke (62%) in the world and is also
a significant contributor to ischemic heart disease2 (49%). In addition the
hypertension is also the number one risk factor attributed to death in the modern
world2. The prevalence rates of Hypertension in India are estimated to be 59.9
and 69.9 per thousand males and females, respectively in urban areas and 35.5
and 35.9 per thousand males and females respectively in the rural areas. Thus we
know that it's a disease of urbanization3.
Furthermore, with the estimated prevalence of hypertension being very
high in India, it is necessary to study the complications associated with
hypertension among the Indian population. Hypertension has a very prolonged
asymptomatic period. However, it is during this period when the silent end organ
damage happens without the patient developing any clinical manifestations. Most
of the times, Hypertension is diagnosed when the patients present with
complications. The long latent period between the development of asymptomatic
3organ damage and the clinical manifestation gives us ample time to initiate
measures to prevent the development of target organ damage.
There are no studies which have regarded the prevalence of asymptomatic
organ damage in patients presenting with systemic hypertension for the first time.
Further, the presence of asymptomatic organ damage also plays a vital role in
patients with stage I Hypertension where the treatment of the condition varies
based on the presence or absence of organ damage. Hence this study was
undertaken to study prevalence of asymptomatic organ damage in systemic
hypertension at the time of presentation. This will give us valuable data regarding
the need to assess end organ damage at the first presentation of hypertension.
This is particularly important in our country given the fact that the screening
programs for non-communicable diseases in our country are virtually non-existent.
The burden to the society due to the complications of hypertension can be
reduced by early diagnosis and regular screening programs at the community
level.
Why Uric acid?
Uric acid has been linked to hypertension in early 1800s4. But the concept
of uric acid as a factor producing hypertension was conceptualized by studies
done in 2000 on rats5. The High uric acid levels were found to induce changes in
the endothelium, which ultimately lead to Systemic hypertension. Uric acid has
since been proven as an independent risk factor for the development of
hypertension and increased uric acid levels has been implicated in the
development of complications6.
4A meta-analysis of data taken from multiple trials done on hypertensive
patients to study the cardiovascular outcomes with uric acid levels showed that for
every standard deviation increment of uric acid there was a significantly increased
cardiovascular risk. This increase in the cardiovascular risk was equal to that of
the increase caused by elevated blood pressure and elevated total cholesterol7.
Uric acid causes cardiovascular damage due to various pathophysiological
mechanisms. The elevated levels of serum uric acid increase the proliferation of
the vascular smooth-muscle cells5. The elevated uric acid also suggests that there
is an activation of an inflammatory pathway as the process of formation of uric
acid results in the generation of many free radicals. In addition, uric acid is
formed from purine analogues, the degradation of which is increased when there
is a destruction of nucleated cells, which includes all the inflammatory cells. The
elevated uric acid also by itself causes activation of inflammatory pathways8.The
other mechanism by which uric acid causes cardiovascular damage is by
promoting platelet activation9.
Uric acid has also been shown to be a good surrogate marker to diagnose
tissue ischemia and is also associated with endothelial dysfunction10. High uric
acid levels have also been shown to play a role in the development of
atherosclerotic lesions11. The main pathophysiological mechanism by which uric
acid causes hypertension is postulated to be the renal ischemia which occurs
secondary to hyperuricaemia. This reduction in the renal blood flow causes
hypertension by renal salt conservation and the activation of the Renin-
Angiotensin-Aldosterone System.
5Why HsCRP?
HsCRP has evolved as the most reliable marker of vascular inflammation and is
considered the prototype downstream marker of inflammation. Out of all the
inflammatory markers studied in hypertension, including IL-6, IL-1ß and TNF-α,  
HsCRP was found to be the most sensitive and specific marker associated with
hypertension. This association was well proven in many studies on Hypertension12.
There is a continuous(linear) relationship between the HsCRP and the
Blood pressure13.And the risk of developing hypertension increases with increasing
HsCRP levels.
HsCRP may also predict the risk of developing hypertension in patients who
are normotensive and the risk increases significantly in those with elevated
HsCRP14. King et al. showed that prehypertensive population (Systolic BP 120-139
mm Hg and/or diastolic BP 80-89 mm Hg) had a significant number of people with
elevated HsCRP compared to normal individuals15 (27.4% vs. 19.8%; p<0.05).
In addition, CRP is also shown to down regulate endothelial Nitric Oxide
synthase(eNOS) mRNA transcription in the endothelium. This results in a decrease
in the release of nitric oxide both basally and on stimulation16. Also, reduced nitric
oxide at the endothelial level is postulated to be an important step in the
development of Hypertension, atherosclerotic events and in vascular
catastrophes17.
6Rationale
From the above it is very clear that there is a need to study the prevalence
of asymptomatic organ damage in India, though we have a huge burden of
hypertensives considering that India has one sixth of the world population. The
screening programs for noncommunicable diseases are in their infancy in our
country. This makes it important to study the prevalence of asymptomatic organ
damage in patients who present with hypertension for the first time.
The role of inflammatory markers in hypertension is not very well studied in
our population, though there is enough evidence to implicate HsCRP and Uric acid
levels in hypertension. This study was done to study the prevalence of
asymptomatic target organ damage in the Indian population and the feasibility of
using Uric acid and HsCRP as surrogate markers to predict target organ damage in
newly diagnosed Hypertensives.
7AIMS OF THE STUDY
8Aims of the study
1. To assess the prevalence of asymptomatic organ damage in patients with
Hypertension.
2. To assess the role of inflammatory markers in causing the asymptomatic
organ damage in patients with hypertension.
9OBJECTIVES OF THE
STUDY
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Objectives of the study
Primary Objective
 To study the prevalence of asymptomatic cardiac and renal damage in
adult patients with treatment naïve systemic hypertension according to ESC
2013 criteria
Secondary objectives
 To study the factors associated with asymptomatic cardiac and renal
damage.
 To determine the sensitivity and specificity of hsCRP and Uric acid to
predict the asymptomatic cardiac and renal damage
 To determine the variations in asymptomatic cardiac and renal damage in
patients with varying levels of hsCRP / Uric acid at the time of diagnosis.
 To determine the variations in the asymptomatic target organ damage with
respect to mean resting heart rate.
11
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Review of literature
The pandemics which have ravaged the world have been changing from
time immemorial. The initial pandemics in the undeveloped world where
predominantly infectious. The pandemics of influenza, plague and smallpox is very
well-known. The other major causes of death before the Industrial Revolution
where famine and floods and other natural disasters. This era has represented a
change in the fundamental way the humans have conquered the elements of the
nature. The quest for supremacy of humankind over the nature has brought with
it its own set of challenges. One of the modern pandemics which we face today is
the burden of noncommunicable diseases which have been brought about by the
unhealthy lifestyle, sedentary activities, dietary changes, and the reduction in the
amount of manual labor due to the increase in the machines. All this has
contributed much to the modern day epidemics of diabetes mellitus, hypertension
and coronary artery disease.
Hypertension befits an important recognition amongst these pandemics.
The amount of population suffering from hypertension is really immense The
global burden of hypertension in 2000 was estimated to be around 26.4
percentage of the adult population and it was estimated 972 million people were
hypertensives. This number was predicted to grow to 1.56 billion people by
202518. The rapid rise in the incidence of hypertension can be attributed to
increased screening and unhealthy lifestyle practices.
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The world health report 2002 states that suboptimal blood pressure is a
leading cause of stroke and it is also an important risk factor for cardiac failure2.
Hypertension is one of the leading causes of Disability adjusted life years
(DALY's). The organ damage caused due to hypertension can lead to disastrous
consequences and most of them are not treatable once they occur. The best way
to manage hypertension is to detect hypertension early and to institute treatment
to prevent the development of complications.
Definition of hypertension:
 Hypertension has been defined as the systolic blood pressure of ≥ 140 
mmHg and/or diastolic pressure ≥ 90 mm Hg, according to the European Society 
of hypertension guidelines 2013. This definition of hypertension almost parallels
itself with the definition given by other authorities like the JNC 7. This definition of
hypertension, however, needs to be taken with deliberate caution. It has been
known that any blood pressure is about 115/75 has been associated linearly with
increased target organ damage2. However, it is at the cutoff of 140/90 that the
treatment of blood pressure with antihypertensives produces significant changes
in morbidity and mortality and hence this is chosen as the cutoff for elevated
blood pressure or hypertension.
Normal blood pressure is defined as a blood pressure of less than 120/80.
The value between the normal blood pressure and hypertension is defined as a
pre-hypertensive stage where these people are at risk of end organ damage and
for transformation into hypertensives with progressive elevation of blood pressure.
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The definition of blood pressure also brings into account the staging of
hypertension. The hypertension has been staged in many different ways. Here in
the study, we follow the European Society of hypertension grading of
hypertension for the sake of uniformity. The table showing the grade of
hypertension is given below (Table 1.).
Table 1. Grading of Hypertension
Grade Systolic BP
(mm Hg)
Diastolic BP
(mm Hg)
Grade I 140-159 And / Or 90-99
Grade II 160-179 And / Or 100-109
Grade III ≥180 And / Or ≥ 110
The Global Burden of Hypertension
The burden of hypertension across the world according to the 2000
estimates was around 26.4% of the world population2. Hypertension was alone
responsible for around 7.6 million premature deaths, accounting for 13.5% of the
global total deaths 19. It was also responsible for 92 million disability adjusted life
years DALY's contributing to around 6% of the global disability adjusted life year
DALY' 19. It was also responsible for 54% of the stroke patients making it the
number one cause of stroke and around 47% of patients with ischemic cardiac
disease2. And paralleling the global trends in hypertension, which was more in the
15
developing countries, 80% of the disease burden occurred in the developing
world19.
In a study done in east Asian population, diastolic blood pressure co-
related well with the increased risk of developing a stroke and ischemic heart
disease and the reduction of the diastolic blood pressure by 7% when it is above
95mm Hg resulted in a significant reduction in the incidence of stroke and
ischemic heart disease20.
A recent study done in rural China, which included 16,364 residents
showed the prevalence of hypertension was around 43.8% and only around
26.2% were aware that they had hypertension and only 22% were on treatment.
Out of all the hypertensives only a mere 3.9% achieved adequate blood pressure
control21.
The Indian Burden of Hypertension.
The diseases in the world have gone through an epidemiological transition.
The transition not only occurs in the type of diseases but also among the group of
disorders. The initial cardiovascular disorders prevalent among the Indian
population were the infective disorders like the rheumatic heart disease, however,
with the epidemiologic transition the lifestyle diseases like hypertension and
ischemic heart disease predominate Indian scenario and most of the South Asian
countries including China22.
In India cardiovascular diseases caused approximately 2.3 million deaths in
1990 and the number is expected to double in the next 30 years. Hypertension is
16
directly responsible for more than half of all stroke deaths in India and a quarter
of all ischemic cardiac deaths in India23. The prevalence of hypertension in India
has been increasing very steadily. It is increased from approximately 1 to 5% in
the 1950s to 12 to 15% in the 90s20. The prevalence of hypertension is much
higher in the urban population, compared to the rural population, however the
gap is getting smaller and smaller as the years go on. This is probably due to the
change in lifestyle of the population.
Most of the studies on hypertension in India are from the western India.
One of the studies done in western India assessed 2122 subjects, who were more
than 20 years of age and it showed the prevalence of hypertension was around
30% in men and 33% in women. By JNC V criteria and a multivariate analysis
showed that age, higher BMI and smoking were independently associated with
prevalence of hypertension. The prevalence of hypertension was also found to
increase along with the age in both men and women24.
A recent study in Chennai showed the crew prevalence of
hypertension overall in Chennai was around 21.1% and an age standardized
prevalence of around 17%. The study also showed hypertension were significantly
associated with age, body mass index and glucose intolerance. The high
prevalence hypertension in an urban city of South India shows that hypertension
is a very common in the south indian population25.
Another study done in Kerala showed the prevalence of hypertension was
around 18.9% between the ages of 25 to 64 and 33.5% between the ages of 45
to 64 years. The prevalence was higher in males than in females in the younger
17
population, while it evened out as the age of the population increased. Central
obesity was found to be a very strong predictor of hypertension in these
patients26.
End organ damage due to hypertension
End organ damage in hypertension is a major cause of morbidity and
mortality. The end organs usually affected by hypertension are the heart, the
kidney, and the blood vessels. The hypertensive end organ damage in the heart
manifests as the hypertrophy of the left ventricle, which leads progressively to a
left ventricular systolic and diastolic dysfunction. The hypertensive damage of the
kidney leads to the microalbuminuria in the early stages due to intraglomerular
hypertension and sustained blood pressure elevation leads to hypertensive
nephrosclerosis and eventually to chronic kidney disease. The hypertensive
damage to the endothelium of the blood vessels initially leads to the stiffening of
the vessel walls. This is reflected by an increase in the central aortic stiffness
which is measured by the carotid-femoral pulse wave velocity. Long-term
hypertension is also known to cause the increase in the carotid intimal medial
thickness. The thickening of the blood vessels leads to a decrease in the
compliance of the vessel and is responsible for the vascular events in
hypertension27.
Asymptomatic organ damage in hypertension:
The asymptomatic organ damage has been defined in the ESC guidelines
for a few years now. The concept of asymptomatic damage derives itself from the
fact that there is a long latent period between the development of hypertension
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and the end organ damage, which is a serious cause of morbidity and mortality.
Hence, it's imperative to identify people who have developed subclinical target -
organ damage to treat them to reverse the condition and to prevent the
development of complications.
The asymptomatic organ damage is characterized by the measurement of
microalbuminuria, hypertrophy by electrocardiography or echocardiography, the
carotid intimal medial thickness and the carotid femoral pulse wave velocity. All
these four indicators of asymptomatic organ damage have been independently
linked to cardiovascular risk in patients with hypertension. Hence, it's imperative
in clinical practice to look for the markers in patients with hypertension, to
categorize the cardiovascular risk and to effectively manage them.
Prevalence of Asymptomatic Organ damage in
Hypertension:
The prevalence of subclinical target organ damage was found initial study
to be very high. The incidence of left ventricle hypertrophy was around 46%, the
prevalence of carotid abnormalities was around 31% and the prevalence of
microalbuminuria was around 12%28. This is very high when compared with the
normal population. The prevalence of very high levels of organ damage in newly
detected hypertensives highlights the importance of identifying and treating them
at the earliest possible time to prevent the development of complications. The
Subclinical target organ damage was not related to age nor to the duration of
hypertension before diagnosis. The organ damage is however related to body
19
mass index, serum triglycerides and in women with higher serum uric acid
levels.28
Microalbuminuria in Hypertension
Microalbuminuria is a very early and are very sensitive marker of renal
damage not only in patients of diabetes mellitus but also in patients with essential
hypertension. Microalbuminuria is an independent predictor of cardiovascular
events in hypertensive patients. Microalbuminuria along with elevated
inflammatory markers like HsCRP have been shown to be elevated in patients with
metabolic syndrome and this probably denotes a high-risk population who were
more prone to end organ damage. From JNC 7 microalbuminuria has been
incorporated as one of the major cardiovascular risk factors29,30.
In a cohort study done between 1994 and 1999 which compared the
microalbuminuria in patients with diabetes and in patients without diabetes and
looked for the relative risk for all-cause death and hospitalization for congestive
cardiac failure showed that the relative risk in patients with and without diabetes
mellitus did not show any difference. The risk of cardiovascular events was similar
in those with diabetes mellitus and in those without diabetes mellitus, even after
adjusting for all other cardiovascular risk factors31.
In another study revealed microalbuminuria and peripheral arterial disease
as risk factors for increased cardiovascular disease and all-cause mortality. It was
found that the relative risk of microalbuminuria was 3.2 when compared to the
relative risk of peripheral artery disease which was 2.4 in causing an increased
cardiovascular mortality. The study also showed that the results were independent
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even after adjusting for age, sex, diabetes, hypertension, HDL and triglycerides,
body mass index, smoking habits and pre-existing ischemic heart disease.This
study showed that the risk is high for microalbuminuria to cause an increase in
the cardiovascular mortality. Microalbuminuria and peripheral artery disease were
found to be mutually independent risk factors for increasing cardiovascular
mortality32.
In the Islington Diabetes survey, microalbuminuria was found in 23% of
newly diagnosed diabetic subjects and in 9.4% of non-diabetic subjects. It was
found that there was a weak correlation between microalbuminuria and systolic
and diastolic pressures. The coronary artery disease was found in 74%
percentage of subjects with microalbuminuria. Even after adjusting for these
factors, including diabetes, impaired glucose tolerance, systolic and diastolic blood
pressures, smoking, age, sex, ethnic origin and BMI, urine microalbuminuria
demonstrated an increased risk for development of coronary artery disease. The
odds ratio was 6.38 for development of coronary artery disease. The study also
showed microalbuminuria was an independent predictor for the development of
coronary artery disease33.
The life study, which was done in an elderly population with left ventricle
hypertrophy and were assigned to receive losartan or atenolol. The study showed
that for every tenfold increased in urine microalbuminuria the hazard ratios
increased very markedly. For every tenfold increase in microalbuminuria, the
cardiovascular mortality increased by 97.7%, stroke by 51%, and myocardial
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infarction by 45% and all-cause mortality by 75%. The results were independent
of whether the patients were diabetic or non-diabetic34.
In the third Copenhagen city heartstudy, whichh was conducted in between
1990 to 1994 and followed up till 1999. The population included men and women
between 30 to 70 years of age and they had microalbuminuria estimated. During
the follow-up 192 patients had died due to coronary artery disease out of a total
of 276 deaths, which was found in the study population. Microalbuminuria in the
upper quartile was associated with an increased risk of coronary artery disease(RR
2.0, 95%CI - 1.4-3.0) and death (RR 1.9, 95% CI 1.5-2.4). This association was
independent of age, creatinine clearance, dyslipidaemia, hypertension or
diabetes35.
Another study done in Denmark involved identifying patients with
hypertension between 1983 and 1984 and had a quantification of urine
microalbumin at the time of the study. They were followed up for a period of 10
years and ischemic heart disease in them was studied using national hospital and
death certificate registers. The study showed that microalbuminuria was very
strongly associated with ischemic heart disease with the relative risk of 3.5 when
adjusted for all other risk factors. The study also showed that borderline
hypertensive patients were also at increased risk of developing ischemic heart
disease36.
All the above studies show that microalbuminuria is an increased risk factor
for development of coronary artery disease and is an independent predictor for
cardiovascular risk irrespective of whether patient is diabetic or not. The studies
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also showed even in the general population urinary microalbuminuria is associated
with an increased cardiovascular risk. Thus the identification of microalbuminuria
and treatment of microalbuminuria is of extreme importance in the management
of hypertension.
In a recent study done in Tamil Nadu the prevalence of microalbuminuria in
hypertensives was studied. The study included a majority of patients with stage II
hypertension and 64 percentage of the population had microalbuminuria. There
was also a significant association between the different hypertensive grades and
the microalbuminuria. The study showed that microalbuminuria in hypertensives is
not a rare entity37.
Reduction in microalbuminuria causes reduction in
the cardiovascular risk
In the LIFE study, the patients were divided post hoc into 4 strata based on
urine microalbumin. The urinary microalbumin was estimated at the baseline and
at 1 year of enrollment into the study. The study patients were divided into 4
groups based on microalbuminuria as (1) The Low baseline/low 1 year, (2) Low
baseline/High 1 year, (3) High base line/Low 1 year and (4) High baseline/high 1
year. Among the four groups the incidence of the cardiovascular eventswase
5.5%, 8.6%, 9.4% and 13.5% respectively. The results conclusively showed that
there was a stepwise reduction in the risk with the decrease in the
microalbuminuria. This is independent of all the other factors which could
confound the results38.
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Left ventricular hypertrophy in hypertension
Left ventricular hypertrophy is one of the commonest complications
associated with the patients with hypertension. The incidence of left ventricular
hypertrophy ranges between 16 to 74% in echocardiographic studies and from 1
to 44% in ECG studies.
A comprehensive review of 20 studies with 48,545 participants, which are
published between 1962 to 2000 showed that the adjusted risk of future
cardiovascular events associated with LVH was found to be between 1.5 to 3.5
with the weighted mean risk ratio of 2.3. The all-cause mortality in the same
study was found to be 1.5 to 8 with a mean risk ratio of 2.5. The study showed
that there was a trend towards was cardiac outcomes with left ventricular
hypertrophy39.
In a study published in 2000, 1925 hypertensives with no complications
underwent an echocardiogram for calculating the LV mass and an ambulatory
blood pressure monitoring. They were followed up for a period of four years.
During follow-up there were 181 major cardiovascular events. The study
participants were divided based on the LV mass into five quintiles separately for
both men and women. The study showed that in men and women the
cardiovascular event rates vary between .8/100 patient years in the lowest quintile
to 4.3/100 patient years in the highest quintile. These results were independent of
all the other risk factors and further there was a risk even below the current upper
limit of normal for the LV mass in the study subjects. The study showed that there
24
was a significant risk associated with LV hypertrophy in patients with
hypertension40.
The increased LV mass is also associated with the risk of sudden cardiac
death in patients with hypertension. In a study done with 50 hypertensive patients
with LVH and 50 normotensive controls the incidence of non-sustained ventricular
tachycardia was significantly increased in patients with left ventricular
hypertrophy. This was also associated with high prevalence of ST-T abnormalities
on the electrocardiography. The clinical importance of these non-sustained
ventricular tachycardia was not known .However the significant number of
patients showing non-sustained ventricular tachycardia might lead us to say that it
might be the cause of fatal arrhythmia in these patients41.
In another study published in 1986, the study was done on 140 men with
uncomplicated hypertension to understand the risks of left ventricle hypertrophy
and cardiovascular events. The study included both echocardiographic and
electrocardiographic criteria for detection of left ventricular hypertrophy. The
study showed that morbid cardiovascular events occurred in patients with LV
hypertrophy at the rate of 4.6 per 100 patient years when compared to the
patients with normal ventricular size where the incidence was 1.4 per 100 patient
years. The electrocardiography showed very few patients with left ventricle
hypertrophy and was not found to be of any predictive value. Multiple logistic
regression showed that LV mass index was the best independent predictor of
future cardiovascular events42.
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Reduction of left ventricle hypertrophy and outcomes:
The reduction in left ventricle hypertrophy has been associated with
improved outcomes in patients with hypertension. There are multiple studies
which have shown that as the LVH decreases the risk of adverse cardiac events
also decreases substantially in this population.
In one of the studies published in 2002, thousand 326 patients with
systemic hypertension who had ECG evidence of LVH were recruited from the
Nordic countries, the United States and United Kingdom. These patients were
randomly assigned to receive either losartan or atenolol with hydrochlorothiazide
as second antihypertensive agent. They were followed up for a mean duration of
4.7 years. The results showed that the cardiovascular outcomes were reduced by
25% with losartan when compared to atenolol. The patients who got losartan had
lower cardiovascular mortality and low total mortality. Losartan decreased the ECG
left ventricular hypertrophy more than atenolol. The study showed that losartan
was much superior to beta-blockers in treating patients with left ventricular
hypertrophy and hypertension43.
Another study, which looked that losartan and atenolol in causing
regression of left ventricular hypertrophy was the LIFE study. The study included
a total of 960 patients with essential hypertension and LVH on screening
electrocardiogram. Of the 960 patients, 457 were treated with losartan and 459
were treated with atenolol. The participants with followed up for more than one
year to study LV mass index. The losartan-based therapy reduced the LV mass
index by 21.7 g/m2 compared to 17.7g/m2 in the atenolol group. This was found
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to be statistically significant. This also showed that angiotensin receptor blockers
are much better than beta-blockers in causing regression of left ventricular
hypertrophy44.
The 4E- left ventricular hypertrophy study was done to study the effects of
eplerenone, enalapril and the combination of enalapril/eplerenone. The study was
done in 202 patients with left ventricle hypertrophy and hypertension. The change
in LV mass was studied with MRI. The change in LV mass from baseline was
significant in all the groups. However enalapril alone (-19.9 g/m2) reduced LV
mass more than eplerenone (-14.5 g/m2) but the combination of enalapril with
eplerenone (-27.2g/m2) reduced the LV mass to the maximum. The study showed
that the combination of eplerenone with enalapril was much better than either
one of them in causing the regression of left ventricular hypertrophy45.
Another large study, which looked at the effect of ACE inhibitors on the
regression of left ventricular hypertrophy, was the HOPE study. The study
included 676 patients with left ventricle hypertrophy into two arms the ramipril
group and the placebo group. There was also 7605 patients did not have left
ventricle hypertrophy, 3814 in the ramipril group and 355 in the placebo group. At
the end of the study 8.1 percentage of patients in the ramipril group had a
development or persistence of left ventricle hypertrophy and 9.8 percentage in the
placebo group had developed of left ventricle hypertrophy. The patients in the
ramipril group also had increased regression of left ventricular hypertrophy
compared with the placebo group. Both of these results were statistically
significant. The effects of ramipril were also found to be independent of the blood
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pressure changes. The patients in the ramipril group also had decreased
cardiovascular death, myocardial infarction and congestive cardiac failure. The
study against shows the regression of left ventricle hypertrophy reduces the
incidence of morbid cardiovascular complications46.
Another meta-analysis looked at the effect of various medications in
reversal of left ventricle hypertrophy in essential hypertension. This study showed
that the decline in left ventricle mass was directly proportional to the decline in
blood pressure and longer the duration of antihypertensive therapy. The study
also showed after adjustments for the different durations of treatment the left
ventricular mass decreased the maximum with ACE inhibitors (13%), followed by
calcium channel blockers (9%), followed by beta-blockers (6%) and diuretics
(7%). There are similar tendencies for decrease with relation to the left ventricle
wall thickness also47.
Patterns of left ventricular geometry in patients with
systemic hypertension
Left ventricular hypertrophy is one of the cardinal manifestations in patients
with hypertension. The left ventricular hypertrophy is one of the adaptive changes
which occurs in the natural history of hypertension. The initial well-known
component of hypertensive organ damage was the left ventricular hypertrophy.
However, as time progressed by people also realized that hypertension also
causes multiple other geometries based on the hemodynamic stressors which are
present in the individual. Based on this concept, the LV geometries were
described as normal, concentric remodeling, concentric hypertrophy and eccentric
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hypertrophy. The diagnoses of these geometries were made on the basis of an
echocardiogram. The LV mass index and the relative wall thickness help define
the of the various LV geometries (Table 2).
Table 2. Left ventricular geometries in Hypertension
Parameter LV Mass Index Relative Wall Thickness
Normal Normal Normal
Concentric remodelling Normal Increased
Eccentric remodelling Increased Normal
Concentric Hypertrophy Increased Increased
Both LV mass index and relative wall thickness are calculated from readings
got from the M-mode in the echocardiography. The formula for calculating both
these indexes are described in the methodology separately.
Pathophysiology of the various LV geometries
The various LV geometries are considered to be adaptive changes in the
heart due to the various changes in the haemodynamic status of the patients in
hypertension.
In patients with concentric remodelling, the remodelling occurs without the
thickening of the wall of the chamber and the chamber becomes more elliptical.
This adaptive remodeling causes the LV to pump more efficiently and maintain the
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cardiac output. Concentric remodeling occurs predominantly in patients with
increased afterload and with a reduced venous return or preload48.
The second LV geometry is the eccentric remodeling, this happens when
the LV mass increases and the thickness of the walls compared to that of the
internal diameter of the LV remains constant. This shows that there is an
increased venous return with a reduced afterload. This results in a dilatation of
the left ventricular chamber to accommodate the increased venous return. This is
essentially the remodeling that occurs due to volume overload48.
The third LV geometry is one which is well described and is the most
serious adverse prognostic factor in patients with hypertension. It is the
concentric hypertrophy of the left ventricle. This happens in patients with an
increased afterload and increased venous return. This results in an increase in the
absolute LV mass and also an increase in the thickness of the left ventricular wall
compared to the internal diameter of the left ventricle. This is the classical
geometry associated with patients with hypertension48.
All of the three ventricular geometries are associated with increased
cardiovascular risk. However the highest risk is in patients with concentric
hypertrophy. The patients with eccentric hypertrophy and concentric remodelling
have an intermediate risk for cardiovascular events in patients with
hypertension48.
In a study done in 43 asymptomatic hypertensive patients and 43 normal
individuals who were well matched showed that there was a significant difference
in left ventricular mass and relative wall thickness in patients with hypertension.
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The LV mass, relative wall thickness and absolute wall thickness were increased
significantly in patients with hypertension49.
In a study published in 2001, the LV geometry in patients with and without
hypertension was studied. The patients were evaluated for systolic and diastolic
function is with M-mode echocardiography. The patients were divided into four
groups as normal LV geometry, concentric remodelling, eccentric hypertrophy and
concentric hypertrophy. The LV systolic function as measured by mid-wall
fractional shortening was found to be decreased in patients with concentric
remodelling and concentric hypertrophy of the heart. The LV diastolic function as
measured by the iso-volumetric relaxation time was also decreased in the above
groups. In a multivariate analysis systolic blood pressure, end-systolic wall stress
and relative wall thickness were independently found to be related to reduction in
mid-wall fractional shortening50.
Carotid Intimal medial Thickness and Hypertension
A Study was done in Iowa in a representative cohort of people were
followed from childhood to the age group of 33 to 42 years which consisted of
346 men and 379 women. The study measured the carotid intimal medial
thickness in all these patients are 12 points. A medical questionnaire was also
completed and the rest factor analysis was done. The study showed that in men
who LDL-cholesterol HDL cholesterol and diastolic blood pressure were predictive
of the increased carotid intimal medial thickness51.
In a study published in 2002, a study was done to study the association
between carotid intimal medial thickness and left ventricular mass index in
31
children who were referred with elevated blood pressure. The study was
conducted in 32 subjects who were untreated new referrals to pediatric
hypertension clinic. The LV mass index is calculated by M-mode echocardiography
measurements and the carotid artery duplex ultrasound were performed in these
patients. The results showed that the prevalence of LVH and increased carotid
intimal medial thickness was around 41% and 28% respectively. The subjects
with an increased carotid intimal medial thickness had a higher LV mass index
(46.8 g/m2 vs 31.4g/m2). Carotid intimal medial thickness also positively
correlated with body mass index interventricular septal thickness and posted wall
thickness. All the results in a study were adjusted for age, sex and BMI52.
The Rotterdam study a case-control approach was done among 7983
patients is more than 55 years. At the base line between March 1990 to July 1993
there was a baseline carotid intima medial thickness, which was measured and
stored on videotape. Determination of incident myocardial infarction and stroke
was predominantly based on hospital discharge records. A total of 98 myocardial
infarction and 95 strokes occurred before 1994. The intimal medial thickness was
measured in all the case subjects and a sample of thousand 373 patients who did
not have a myocardial infarction. The results showed that the stroke risk
increased with an increasing intimal medial thickness. For the myocardial
infarction the odds ratio was around 1.43(95% CI 1.16 to 1.82). The study
showed that there was an increased risk from both cerebrovascular events and
coronary events with increased carotid intimal medial thickness53.
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The European Lacipidipine study of atherosclerosis was prospective,
randomized, double-blind multinational trial which was published in 1998. The
study compared for your treatment based on a calcium antagonist lacidipine with
atenolol on development of carotid artery wall alterations in patients with mild to
moderate hypertension. The study cohort included 2259 patients. The carotid
intimal medial thickness was measured at 12 sites and was expressed as the
mean that these sites. A multivariate analysis was done to find the clinical
variables which correlated with increased carotid intimal medial thickness. The
carotid intimal medial thickness was found to be correlated in the following order
with age, 24-hour ambulatory pulse pressure, sex, LDL-cholesterol, serum
triglycerides, smoking and systolic blood pressure. This also shows that carotid
intimal medial thickness is found to correlate well with patients with hypertension
and they predict the risk of end organ damage54.
Another study, verapamil in atherosclerosis and hypertension study was
done to see the effect of verapamil and chlorthalidone on carotid intimal medial
thickness in patients with hypertension. The study 498 hypertensive patients from
Italian centers were randomized to either verapamil or chlorthalidone. A B mode
ultrasound scan was done at baseline and at three months, 12 months, 24
months, 36 months and at 48 months of treatment. The carotid will medial
thickness was measured at six sites and the mean maximal thickness was used for
analysis. The study showed that the slope a decrease in the carotid intimal medial
thickness was much higher in patients in the verapamil group (-0.082mm) versus
the chlorthalidone group (0.037mm/year) and the value was statistically
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significant. The study showed that calcium channel blockers were more effective
in reducing the carotid intimal medial thickness in patients with hypertension55.
In a study published in 2005, blood pressures, lipid profile, carotid intimal
medial thickness in adolescents with and without obesity were measured. The
study showed that 24 hour blood pressure, daytime and nighttime systolic BP was
high in the obese adolescents. Obese subjects also had elevated triglycerides and
low HDL when compared to the non-obese adolescents. The obese adolescents
were also found to have higher mean carotid intimal medial thickness than the
nonobese adolescents. The study again showed BP and lipid profile were very
closely related to the carotid intimal medial thickness56.
In another study which was done in Sweden, carotid intimal medial
thickness and occurrence of the carotid plaque were studied in adult men with
borderline systemic hypertension along with age-matched normotensive controls.
The B mode ultrasound was used to assess intimal medial thickness. The study
showed that there was a slight increase in the carotid intimal medial thickness in
the borderline hypertensive group (0.73 vs 0.69mm p=0.07). The difference was
seen better in the right carotid artery (0.72 vs 0.67mm P<0.05). The incidence of
the carotid plaque was also higher in the borderline hypertensive group, 26%
versus 16% in the control group. The other determinants in the study, which are
shown to be significantly related to the carotid intimal medial thickness were age
and HDL cholesterol57.
In another study done in Finland which included 1224 Eastern Finnish men
between the ages of 42 to 60 years to look the determinants of carotid intimal
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medial thickness. The study showed that the maximum carotid intimal medial
thickness varied between .48 mm to 4.09mm. The regression analysis showed
that the carotid intimal medial thickness was related to age, blood pressure,
smoking and LDL cholesterol concentration. The study also shows the importance
of blood pressure in contributing to an increased carotid intimal medial
thickness58.
In a recent study done in Beijing published in 2014 a total 3324 patients
were enrolled in the study and 2895 people with carotid ultrasound were
analyzed. The study showed that the incidence of carotid mean intimal thickness,
maximum carotid intimal thickness and the incidence of coronary plaque all
increased in proportion to the blood pressure (p<0.01). These values were
significant even after adjusting for diabetes, hypercholesterolaemia, elevated
HSCRP, smoking, age, obesity and sex. The study against shows the importance
of hypertension in causing accelerated atherosclerosis manifesting as an increased
carotid intimal medial thickness59.
Carotid femoral pulse wave velocity and Central aortic
stiffness
One of the other important predictors of asymptomatic organ damage in
hypertension is the increase in the Central Aortic stiffness. This is considered one
of the earliest events in the vascular changes which are caused due to
hypertension. The increase in the arterial stiffness leads to the increase in the
cerebrovascular disease and the coronary artery disease in patients with
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hypertension. The carotid femoral pulse wave velocity is the measurement of the
central aortic stiffness.
It is measured in many different ways. There are commercially available
systems which can measure carotid femoral pulse wave velocity. However, it can
also be measured with an echocardiography machine which records ECG
concurrently. However, since measurement with an echocardiography machine
will occur in two different cardiac cycles, if the heart rate is irregular then the
values will be incorrect.
Many studies have shown the importance of the carotid femoral pulse wave
velocity in determining the risk in patients with hypertension. Below are a few
studies which have shown the importance of carotid femoral pulse wave velocity
in predicting the risks in patients with hypertension.
In a study done in France, 710 patients with essential hypertension were
recruited and the factors influencing aortic pulse wave velocity was studied in the
population. The atherosclerosis alterations were defined on the basis of clinical
events. The patients who had no clinical events, cardiovascular risk estimation
with the use of the Farmingham equation was done. The study showed that a
higher pulse wave velocity was associated with a higher atherosclerosis alteration
even after adjusting for all the confounding factors. Further, patients with higher
cardiovascular risk, according to the Farmingham equation were found to have
increased pulse wave velocity. The odds ratio of being in the high cardiovascular
mortality group (>5% for 10 years) for the patients in the upper quartile of the
pulse wave velocity was 7.1% (95% CI 4.5-11.3). A pulse wave velocity > 13 m/s
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was found to be strongest independent predictor of cardiovascular mortality. The
study shows that the aortic pulse wave velocity significant contributor to
cardiovascular mortality in patients with hypertension60.
In a study done in France just published in 2000, 1290 subjects with
normal blood pressure or elevated blood pressure were divided into three groups
based on the calculated creatinine clearance. All these patients also had the blood
pressure, aortic pulse wave velocity measured. The study showed that in the 112
patients with hypertension the aortic pulse wave velocity correlated significantly
with creatinine clearance even after adjusting for confounding factors. The
increase in stiffness of the aorta was also associated with a significant decrease in
the GFR. This assumes significance in view of the well-known fact that in patients
with end-stage renal disease central aortic stiffness is very high. Central aortic
stiffness might also predict early renal dysfunction in patients with hypertension61.
There are many studies which have shown aortic pulse wave velocity is an
independent risk factor for cardiovascular mortality but they were all indirect
measures. In a study done in France in 2000 it was decided to study the
relationship between aortic stiffness and cardiovascular mortality in hypertensive
patients directly. The study included 1980 patients who had at entry measurement
of carotid femoral pulse wave velocity. These patients were followed up over a
mean of 112 ± 53 months. The logistic regression analysis was done to estimate
relative risk of cardiovascular deaths and it was found that carotid femoral pulse
wave velocity has an odds ratio of 2.35 (95% CI 1.76 to 3.14, p<0.0001) for the
development of cardiovascular events. The study also showed carotid femoral
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pulse wave velocity were significantly associated with all-cause and cardiovascular
mortality independent of age, diabetes and a previous history of cardiovascular
disease. The study showed that carotid femoral pulse wave velocity was a strong
and an independent predictor of cardiovascular mortality in a cohort of
hypertensive patients62.
In another longitudinal study done in France and published in 2002, 1045
hypertensives were evaluated with carotid femoral pulse wave velocity to
document the aortic stiffness. The risk assessment was done with a farmingham
risk score and they were followed up for a period of 5.7 years. The coronary
events and all cardiac events served as the outcome variables. During follow-up
there were 53 coronary events and 97 totalled cardiovascular events. In a
univariate analysis, the relative risk of developing a cardiovascular event increased
with the increasing level of pulse wave velocity. This was statistically significant
even after adjusting for multiple risk factors63.
The aortic stiffness is not only a predictor of cardiovascular events, but also
has a role in predicting the development of cerebrovascular disease. In a
longitudinal study which included 1715 essential hypertensive patients with no
prior history of cardiovascular or cerebrovascular disease, the carotid femoral
pulse wave velocity was recorded at baseline. These patients were then followed
up for a period of 7.9 years. During follow-up there was an occurrence of 25 fatal
strokes. The pulse wave velocity predicted the occurrence of stroke in this
population. There was a relative risk increase of 1.72 (95% CI 1.48-1.96,
p<0.0001) for every standard deviation increase in pulse wave velocity. This
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increase in risk persisted even after adjusting for all the classical risk factors for
developing a stroke64.
The reason for the development of stroke in hypertension is supposedly
due to the cerebral small vessel disease. In a study done in the Netherlands it was
decided to study the effect of central aortic stiffness to the development of small
vessel disease in patients with hypertension. 167 hypertensive patients with no
history of cardiovascular, cerebrovascular disease with untreated hypertension
were admitted into the cohort. These patients had the measurement of blood
pressure, carotid femoral pulse wave velocity and the volume of white matter
intensities and the lacunar infarcts an MRI. The multivariate analysis done showed
that the pulse wave velocity even after been adjusted for sex, age, mean arterial
pressure, heart rate and brain volume was significantly associated with the
volume of white matter hyperintensities (regression coefficient: 0.041 - 95%
Confidence Interval: 0.005 to 0.078; p<0.05). The study showed that aortic
stiffness is also a predictor of cerebral small vessel disease in patients with
hypertension65.
The effect of aortic stiffness in patients in patients with hypertension is
very well-known. However, it is important to also know if with treatment with
antihypertensives will improve arterial stiffness in these patients and cause
reduction in the morbidity and mortality. A few studies were done in this regard.
One of the studies which was published in 2001 looked at the effect of
perindopril on aortic stiffness in patients with hypertension. A total of 2187
patients were enrolled in the study. 1703 patients completed the study. The
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patients were treated for six months with perindopril 4 mg which was increased to
8 mg if the blood pressure was not controlled. If the blood pressure was not still
controlled, then a diuretic was added. The study showed that there were
significant decreases in the carotid femoral pulse wave velocity obtained at two
months and six months with the initiation of therapy with perindopril (-1.1 ± 1.4
m/s). The study showed that treatment of hypertension with ACE inhibitors might
result in a favorable change in the aortic stiffness66.
Another study was done in Poland to look at the effect of calcium channel
blockers, ACE inhibitors and ARB's on the aortic stiffness. The study included 118
patients were randomized to either of the three groups. The group one was
treated with amlodipine, the group two was treated with quinapril and the group
three was treated with losartan. The aortic femoral pulse wave velocity was
measured at baseline, at three months and at six months. The blood pressure
decreased equally in all the three groups. Among the patients with comparable
blood pressure values, there was a significant decrease in the pulse wave velocity
in the quinapril treated patients when compared to the baseline. The other two
groups did not show a significant decrease. The study showed that ACE inhibitors
are the best drugs to reduce the aortic stiffness in patients with hypertension67.
Looking at all the studies which looked at the carotid femoral pulse wave
velocity, we now come to the conclusion that carotid femoral pulse wave velocity
is a significant predictor of cardiovascular and cerebrovascular risk in patients with
hypertension. It is an independent predictor of mortality in these patients. The
treatment of hypertension especially with ACE inhibitors produces a decrease in
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the Central aortic stiffness. However, further studies need to be done if this
reduction in the carotid femoral pulse wave velocity will translate into a reduction
in the cardiovascular and cerebrovascular risk.
Hypertension and uric acid
Serum uric acid is often considered as a predictor of cardiovascular risk.
Normally, uric acid peaks in men are higher when compared to women. The other
conditions were uric acid increases are in patients with insulin resistance,
metabolic syndrome and dyslipidaemia. Uric acid is excreted by the renal tubules
and any reduction in the GFR causes a reduction in the unit excretion and
increases the uric acid levels. The diuretics also increase uric acid levels by
promoting uric acid reabsorption.
The serum uric acid is elevated in around 25% of the hypertensive
patients68. The pathophysiological mechanisms behind the increased uric acid level
in hypertension are described below.
1. Hypertension causes a decrease renal blood flow which will stimulate the
reabsorption of uric acid.
2. The decrease in the local tissue perfusion increases the production of lactate
and lactate competitively blocks the uric acid secretion in the proximal tubule.
3. Ischaemia itself increases the uric acid synthesis.
4. When ischemia occurs, ATP is degraded to adenine and xanthine and this
causes the increased uric acid production.
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5. During ischemia, there is also an increased production of xanthine oxidase69.
All these factors lead to the increase in serum uric acid in patients with
hypertension.
Serum uric acid is also implicated in the development of pro-inflammatory
state. Uric acid causes endothelial dysfunction by causing an impact nitric oxide
release from the endothelium. Uric acid also causes increased platelet
adhesiveness and causes activation of platelets, which may also be a part of
endothelial dysfunction caused by uric acid70.
Uric acid also directly causes vascular smooth muscle proliferation in the
laboratory conditions. The urate which enters the endothelial cell through the
organic and transporters causes the up-regulation of the platelet derived growth
factor A and the PDGF alpha receptor mRNA. Uric acid also stimulates a synthesis
of monocyte chemoattractant protein-1 in the vascular smooth-muscle cells
interact. MCP-1 plays a very important role in atherosclerosis71, 8.
Uric acid was studied in rats in a study in Mazzali et al. They caused
hyperuricaemia in one set of rats by feeding them with and uricase inhibitor and
another set of rats were used as controls. The hyperuricaemic rats developed
hypertension over a period of three weeks while the control rats were
normotensive. A direct relationship was found between blood pressure and uric
acid levels. The kidneys under light microscopy were normal, however
immunohistochemical stains showed and ischemic type of injury and macrophage
infiltration. The rats, which were hyperuricaemic also exhibited an increase in the
juxtaglomerular renin and reduced nitric oxide synthase in the macula densa5.
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Various studies have been done which evaluated the Association between
hypertension and uric acid levels. One of them was the Olivetti heart study. It was
a longitudinal study which looked for these factors for coronary artery disease at
the Olivetti factory in Italy. The patients were screened at baseline, at five years
and at 12 years follow-up. The study showed that serum uric acid were
significantly related to age, systolic blood pressure, diastolic blood pressure, total
cholesterol, BMI and triglycerides. Logistic regression analysis showed that
elevated serum uric acid levels was associated with an increased risk for
development of hypertension (RR - 1.23 CI - 1.07-1.39 p=0.011) after
adjustments for the confounding factors72.
In another study, which was done in the Farmingham study participants.
The serum uric acid levels were tracked in the 3329 subjects who had no
hypertension at the base line. At four years follow-up from the baseline 458
persons developed hypertension. The rates of incidence of hypertension increased
progressively from 9.8 % in the lowest quartile of uric acid to 15.6% in the
highest quartile of uric acid. The odds ratio was 1.17 with a 95% confidence
interval of 1.01 to 1.23. The study showed the uric acid level was an independent
predictor of hypertension incidence73.
The Osaka health survey looked at the Association of serum uric acid with
risk of hypertension and type II diabetes. The study enrolled 6356 Japanese men
aged 35 to 60 years who at the time of enrollment had normal blood pressure,
normal glucose tolerance and no history of diabetes or hypertension. They were
followed up for a period of 61716 person years. There were 639 confirmed cases
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of hypertension and 454 confirmed cases of diabetes. The serum uric acid level
was significantly associated with the risk of developing hypertension. The risk of
development of hypertension in the fifth quintile of uric acid was 2.01 (CI 156-
2.60). The increased uric acid level was not associated with the development of
diabetes. The study again showed elevated serum uric acid level was a risk factor
for development of hypertension74.
The other study that supports the causal role of uric acid in causing
hypertension is the normative ageing study published in 2006. The study had
enrolled to 2280 men and had data for 2062 men for analysis. 892 men had
developed hypertension over 21.5 years of follow-up. The uric acid significantly
and independently predicted the development of hypertension in both age-
adjusted and multivariate analysis75.
The above-mentioned studies show that uric acid significantly related to
hypertension and also causes of pro-inflammatory state which increases the risk
for cardiovascular and cerebrovascular diseases also. Uric acid has a causal role in
hypertension and also plays an important role in the renal damage in hypertension
by causing arteriolar damage to the kidney and finally resulting in nephrosclerosis
and causing microalbuminuria. Uric acid has therefore a causal as well as a
pathogenetic role in the worsening of systemic hypertension. These factors make
uric acid and interesting target to see if it is elevated in patients with
asymptomatic organ damage.
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Inflammatory markers in hypertension
Hypertension is being considered a chronic low-grade inflammatory state.
This is because hypertension is associated with an increase in the level of various
inflammatory markers. There have been many studies which had looked at
inflammatory markers in hypertension. The most studied ones are HsCRP,
interleukin 6, interleukin one beta and TNF alpha. These are the inflammatory
markers which have been shown to consistently be elevated in many trials which
have been done in patients with hypertension.
HsCRP in patients with hypertension
HsCRP is the most important downstream marker of inflammation. It is
associated with hypertension and it's the most sensitive and specific marker as of
now in patients with hypertension12.
CRP is shown to induce the expression of MMP1. MMP1 causes plaque
instability. CRP also up regulates interleukin 8 in aortic endothelial cells and it
causes Major Chemoattractant protein – 1 (MCP-1) mediated chemotaxis. CRP
also attenuates endothelial progenitor cell survival and differentiation by inhibiting
nitrous oxide76.
CRP also decreases eNOS mRNA transcription and upregulates diverse
adhesion molecules, causing a pro-inflammatory and a pro-atherosclerotic state.
CRP also up regulates NFKB signaling and causes decreased survival of endothelial
progenitor cells. It also augments the angiotensin I receptor in the vascular
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smooth-muscle cells. All these together make CRP an important marker to identify
endothelial dysfunction77.
In a study done in 2000, 506 men with coronary heart disease or non-fatal
MI along with 1025 controls who were free of any cardiovascular disease were
selected from 5661 men who had given blood samples between 1978 to 1980.
The results show that compared with the men with the lowest tertile of C-Reactive
protein, the men in the highest tertile of C-Reactive protein had an odds ratio of
2.134 developing an acute coronary event78.
In the patients who had been enrolled in the Farmingham Study, in 1980 to
1982 had CRP levels measured during follow-up. During the next 12 to 14 years,
196 strokes occurred in the population. The highest CRP quartile at baseline had
two times the risk of an ischemic stroke independent of the age of the person.
Thus the study showed that CRP is an independent predictor of an embolic
disease and stroke in patients79.
In the CAPTURE trial with studied the intervention of adding abciximab
before and during coronary intervention in refractory and stable angina the
investigators also look for long-term cardiovascular complications. They are
studied using troponin T and CRP at baseline. It was found that elevated CRP at
baseline was associated with an increased risk for subsequent cardiovascular
events80.
In another study published in 2003, a prospective cohort study that had
begun in 1992 was taken and CRP was done on the baseline samples provided in
1990. These individuals who are normotensive were followed up over a period of
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more than 7.8 years. During follow-up out of the 20525 female professionals 5365
women developed hypertension. The risk of developing hypertension in the
highest quintile of CRP was 2.5 times the risk associated with the lowest quintile
of CRP. The study showed that there was a significant risk of developing
hypertension in patients with elevated CRP levels13.
In another study by King et al, the relationship of CRP in blood pressure
across a range of blood pressure categories including the pre-hypertension was
studied. The data were collected from 1988 to 1994 from the third National health
and nutrition examination survey. It was found that prehypertensive subjects had
higher prevalence of elevated CRP than normal people(27.4% versus 19.8%,
p<0.05). CRP and the blood pressure also positively correlated across a wide
range of blood pressure categories even after adjusting for potential
confounders15.
There is also an increasing evidence to say that CRP plays an increasing
role in the atherogenesis in blood vessels. CRP binds with the lipoproteins and
activates the complement pathway. CRP has often found deposited in the arterial
wall in the atherosclerotic lesions. Thus CRP might play an important role in
atherogenesis81.
CRP also modulates the roles of various chemokines including MCP-1 which
causes atherosclerosis. It also causes an inhibition of the stimulated and basal
Nitric oxide release and contributes to the arterial stiffness16,82. CRP also induces
the peripheral blood monocytes to synthesize tissue factor and causes the
increase in the procoagulant and the pro-inflammatory state83.
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Thus HsCRP and uric acid play important role in modulating the
inflammatory pathways and thereby causing hypertension. The increased
inflammatory markers are also associated with increased morbidity and mortality
in the patients with hypertension. They also associated with increased end organ
damage in the patients with hypertension.
.
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Materials and Methods
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Materials and Methods
Inclusion Criteria
1. Age : 30 to 60 years.
2. SBP>140mm Hg or DBP>90 mm Hg. (2 readings on 2 separate occasions)
Exclusion Criteria
1. Patients on antihypertensives or statins.
2. Patients with any acute febrile illness.
3. Patients with connective tissue disorders.
4. Patients with history suggestive of secondary hypertension.
5. Patients with autoimmune disorders.
6. Patients with tuberculosis.
7. Patients with malignancies.
8. Patients with pregnancy related hypertension.
The patients included in the study were selected between the age of 30 to
60 years to exclude patients with secondary hypertension. The exclusion criteria
also excluded patients on antihypertensives or statins as they have been shown to
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cause a reduction in inflammatory markers like HsCRP. The patients with acute
febrile illness, connective tissue disorders, autoimmune disorders, malignancies,
active tuberculosis were excluded as they will also have elevated inflammatory
markers. Patients with pregnancy related hypertension were excluded as they will
form the vulnerable population.
Methodology
Patients presenting to the medicine outpatient department with a diagnosis
of newly detected hypertension and satisfying the inclusion criteria and who are
willing to participate in the study were recruited in the study after obtaining a
signed informed consent. The recruitment was carried out between November
2013 and August 2014. The patients who were found to be hypertensive for the
first time and was not on antihypertensives were recruited. Those of them who
had diabetes, pregnancy, fever and other diseases like tuberculosis, malignancies
were excluded. In the patients who were included in the study, the blood pressure
was checked twice at least one hour apart on two separate occasions each. If the
blood pressure measurements taken two hours apart was elevated, then the
patients were included in the study.
The patients who were included in the study were initially screened for
evidence of any secondary hypertension with a questionnaire. The basic
demographic data, the blood pressure measurements and the height, weight
, the abdominal circumference recollected at the time of inclusion. The patients
were also evaluated to see if they have any signs of secondary hypertension like a
cushingoid habitus, the subclavian bruit, to see if there are any differences in
51
pulses between the four limbs, any signs of thyroid disease and abdominal
murmurs. Any patients who had history suggestive of secondary hypertension
were excluded from the study.
The patients who had been included in the study were then asked to report
back after doing the blood and urine investigations, and the ECG and the
echocardiography tests. The information was then gathered from the hospital
information system and was entered in the study.
The patients were then informed about their status of asymptomatic organ
damage, according to the ESC 2013 criteria and they were further referred to the
medicine OPD for management of their hypertension and any end organ damage
if present.
Since it was a cross-sectional study, the patients were not followed up any
further for the study. They were, however, followed up and managed in the
medicine OPD's after the initial assessment, data collection and information given
to the patients regarding their cardiac and renal status.
Type of study: cross-sectional study
Institutional Research Board (IRB) Clearance
The study was submitted to the institutional research committee for the
review of the study methodology and to address any ethical issues in the study.
The study was presented to the IRB review committee on 9.10.2013, IRB Minute
Number: 8487. There were a few suggestions regarding the study, which were
52
incorporated into the study, and the final permission was granted on 25.11.2013
to conduct the study.
STUDY DEFINITIONS
Hypertension
Hypertension is defined as values ≥140 mmHg systolic blood pressure and/or ≥90 
mm Hg diastolic blood pressure.
1. The clinical criteria for hypertension is average of 2 or more seated blood
pressure readings during each of the two or more hospital visits at least
one week apart.
2. Hypertension is clinically defined as the blood pressure at which the
institution of therapy produces significant changes in morbidity and
mortality.
3. The office pressure measurement of blood pressure is considered the gold
standard for diagnosis and treatment of hypertension
Staging of hypertension
Staging of hypertension was done according to ESC 2013 criteria84 (Table
3).
Table 3. Grading Of Hypertension
Hypertension Grade Systolic Blood Diastolic Blood
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Pressure Pressure
Grade I 140 - 159 mm Hg And / Or 90-99 mm Hg
Grade II 160 - 179 mm Hg And / Or 100-109 mm Hg
Grade III ≥ 180 mm Hg And / Or ≥ 110 mm Hg
Measurement of blood pressure
1. Make the patient said calmly for 3 to 5 minutes before recording blood
pressure.
2. Take at least one to two blood pressure readings spaced 2 to 3 minutes
apart and if they are grossly different than consider taking one more
reading and consider the average of two readings which are closer to each
other.
3. Consider taking repeat blood pressure measurements in patients with
irregular heart rate example atrial fibrillation.
4. The width of the blood pressure cuff should be at least 40% of the
circumference of the arm the length of the cuff should cover at least 80%
of the circumference of the arm being measured.
5. The measurements should be taken with the cuff and the level of the heart.
6. While using the auscultatory method, the Korotkoff phase I is taken as the
systolic blood pressure and Korotkoff phase II is taken as the diastolic
blood pressure.
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7. Blood pressure during the first visit is checked both upper limbs to detect
any subtle variations in the blood pressure. If there are minimal differences
in the blood pressure between the bilateral upper limbs the highest blood
pressure recorded is taken as the blood pressure.
8. To measure the heart rate for at least thirty seconds after the second blood
pressure measurement to document the same.
The blood pressure was measured in all patients with a Heine Gamma G5 aneroid
Sphygmomanometer.
Abdominal circumference measurement:
The abdominal circumference was measured at the narrowest point
between the lower border of the lowest rib and the upper border of the iliac crest.
The readings were done with the standard measuring tape in centimeters. The
minimum reading possible was 1 mm. The values were rounded to the nearest
centimeter.
Height and weight measurement
Height was measured with a standard measuring scale pasted on the wall
with the readings in centimeter. Sensitivity of the scale was 1 cm.
Weight was measured on a digital scale with sensitivity of 1 g. The
readings obtained were rounded off to the nearest kilogram.
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Markers of Asymptomatic organ Damage
Table 4. Asymptomatic Cardiac Damage84
ECG Criteria Sokolow-Lyon index (SV1 + RV5 >3.5 mV)
Modified Sokolow-Lyon index
(largest S-wave + largest R-wave >3.5 mV)
Cornell voltage QRS duration product (>244 mV*ms)
ECHO Criteria LV Mass Index (LVMI)
Men >115g/m2; women >95g/m2
Relative Wall Thickness (RWT) > 0.42
Table 5. Asymptomatic Renal Damage84
Chronic Kidney Disease with eGFR 30–60 ml/min/1.73 m2 (BSA)
Albumin–creatinine ratio >29 mg/g (preferentially on morning spot urine)
Table 6. Types of Left Ventricular geometry48, 84
Left Ventricular Geometry LV mass Index Relative Wall
Thickness
Normal Geometry Men: <115 g/m2
Women: <95 g/m2
<0.42
Concentric Remodelling Men: <115 g/m2
Women: <95 g/m2
≥0.42
Eccentric Hypertrophy Men:≥ 115 g/m2
Women:≥ 95 g/m2
<0.42
Concentric Hypertrophy Men:≥ 115 g/m2
Women:≥ 95 g/m2
≥0.42
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The formulae used in calculation of various indices in
the study:
1. Body mass index (kg/m2) = weight in kilograms / height in meters2
2. Mean Systolic blood pressure (mm Hg) = (SBP1+SBP2+SBP3+SBP4) /4
(SBP1, SBP2, SBP3, SBP4 are discrete systolic blood pressure readings taken individually
as described in the procedure)
3. Mean Diastolic Pressure (mm Hg) = (DBP1+DBP2+DBP3+DBP4)/4
(DBP1, DBP2, DBP3, DBP4 are discrete diastolic blood pressure readings taken
individually as described in the procedure)
4. Mean Heart Rate (bpm) = (HR1+HR2+HR3+HR4)/4
(HR1, HR2, HR3, HR4 are heart rate readings taken along with the 4 blood pressure
readings.)
5. Body Surface Area85 (m²) = 0.20247 x Height(m)0.725 x Weight(kg)0.425
6. Sokolow Lyon Criteria86 (mV) : S wave in V1 + R wave in V5 > 3.5 mV
S wave in V1 – Amplitude of S wave in V1 lead in mV, R wave in V5 – Amplitude of R
wave in V5 Lead in mV
7. Modified Sokolow- Lyon Criteria (mV): largest S-wave + largest R-wave >
3.5 mV
Largest S wave – Amplitude of largest S wave in the precordial leads. Largest R wave –
Amplitude of the largest R wave in the precordial leads.
8. Cornell Voltage product Criteria87 (mV . ms):
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[(R wave aVL + S wave in V3) x QRS duration] >244 mV · ms [For Men]
[(R wave aVL + SV3 + 0.8 mV) × QRS duration] > 244 mV · ms [For women]
R Wave aVL – Amplitude of the R wave in Lead aVL, Swave in V3 – Amplitude of the S
wave in Lead V3, QRS Duration – Duration of the QRS complex in the ECG.
9. LV Mass88 (g) = 0.8{1.04[([LVEDD + IVSd +PWd]3 - LVEDD3)]} + 0.6
LVEDD – Left ventricle End diastolic diameter in mm, IVSd – Interventricular septal
thickness in Diastole in mm, PWd – Posterior Wall thickness in diastole in mm.
10. LV Mass Index88 (g/m2) = LV Mass (in gm) / Body Surface area (BSA in m2)
11. Relative Wall Thickness88 = (2*PWd) / LVEDD
PWd – Posterior Wall thickness in diastole in mm, LVEDD – Left ventricle End diastolic
diameter in mm.
12. eGFR89 (ml/min/1.73m2) = 175 x (Creat)-1.154 x (Age)-0.203 x (0.742 if
female) x (1.212 if African American)
Creat – Serum Creatinine in mg/dl, Age – Age in years
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Methodology adopted in doing various Biochemical
investigations in the study
Investigation Name Method used
Fasting Glucose Hexokinase Method
Total Cholesterol
LDL Cholesterol
HDL Cholesterol
CHOD-PAP (Cholesterol Oxidase - phenol +
aminophenazone) method
CHE/CHO/POD Direct Method
Enzymatic
Serum Sodium Ion Selective Electrode, indirect
Serum Potassium Ion selective Electrode, Indirect
Serum Creatinine Jaffe's Method, Compensated
Serum HsCRP Nephelometry
Serum Uric Acid Enzymatic uricase-Peroxidase method
Urinary Microalbumin Immunoturbidometry
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Statistical Analysis
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Statistical Analysis
The statistical analysis was performed in this study as below.
 The prevalence of the asymptomatic organ damage was calculated using
the formula
 Prevalence = Number of patients with the problem at a given time
--------------------------------------------------
Total population included in the study
 The evaluation of HsCRP and Uric acid with the asymptomatic organ
damage will be done by dividing the HsCRP and Uric acid into tertiles and
comparing the asymptomatic organ damage between the tertiles with
Analysis of Variance (ANOVA)
 A Univariate and Multivariate analysis will be done to see if there is any co-
relation between the risk factors and the inflammatory markers, HsCRP and
Uric Acid.
 All the statistical analysis was done using SPSS Software version 21 by IBM
Corporation.
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Results
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Results:
The total number of patients recruited in the study was 106. Of the 106
included patients only 98 had complete data and they were included in the
analysis. The rest of the patients were not included in the analysis as they had
incomplete data.
Demographic characteristics.
Of the 98 patients, 57 were males and 41 were females (Figure 1). They
were from diverse backgrounds. The population included predominantly patients
from Tamilnadu, Andhra Pradesh, Bihar, Jharkhand, West Bengal and Bangladesh
as they were the most common population catered in the hospital.
Figure 1. Sex Distribution
n=57
n=41
0 10 20 30 40 50 60
Males
Females
Sex Distribution (n=98)
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Mean age of presentation was 47.03 years and the Standard deviation was
8.3 years. The minimum and the maximum ages in the study were 30 years and
61 years respectively (Figure 2).
Figure 2. Age Distribution of hypertensives with normal curve
Past History In patients with Hypertension
Among the patients who were included in the study, 39 (39.8%) had a family
history of hypertension or coronary artery disease in the first degree relative.
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Of the population studied, 3.1% (n=3) had a family history of dyslipidemia
in a first degree relative. Around 22.2% (22) were smokers or have had a
significant smoking history in the past. Of the studied population, 31.3% (n=31)
had clinical symptoms of snoring or a history of obstructive sleep apnea, but none
of them were on any treatment for the same. 1 patient (1%) had a history of low
birth weight present (Figure 3).
Figure 3. Significant Past History.
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History Suggestive of Secondary Hypertension
Any history of secondary hypertension was also studied in the population.
Only 2% had a family history of Chronic kidney disease but they were all related
to diabetes in the individuals.
Figure 4. History Suggestive of Secondary Hypertension
The people included in the study didn't have any symptoms related to the
renal disease, recurrent urinary tract infections or hematuria in the past. None of
them had any history suggestive of a thyroid illness nor were taking any anti-
thyroid medication or thyroxine supplements. None of them had any symptoms
suggestive of a pheochromocytoma like repetitive episodes of sweating,
headache, anxiety, palpitations. None of the patients studied had episodes of
tetany or weakness suggestive of a parathyroid dysfunction.
2%
0%
0%
0%
0%
0%
0 0.5 1 1.5 2 2.5
Family History of Chronic Kidney Disease
Symptoms suggestive of renal disease
History of Thyroid illness
History Suggestive of Pheochromocytoma
Drugs causing Hypertension
History of parathyroidism
History Suggestive of Secondary
Hypertension (n=98)
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None of the population studied were on the drugs which are known to
cause hypertension like oral contraceptive pills, vasoconstrictive nasal drops,
glucocorticoids or mineralocorticoids and Non steroidal anti-inflammatory drugs
(NSAIDS).
Symptoms at Presentation
The symptoms with which the patients presented to us were also studied in
this study. The symptoms were divided into the four major symptom complexes
into symptoms suggestive of cardiac involvement, symptoms suggestive of
nervous system involvement, symptoms suggestive of renal involvement and the
symptoms suggestive of peripheral arterial disease.
Nervous System Complaints at presentation
The symptoms at presentation were analyzed to see the profile of the
patients present. The most common complaint was Vertigo with 46.9% (n=46)
patients complaining of it. The headache was present in 41 patients (41.83%) and
was the next commonest nervous system complaint in the studied population. The
other complaint was blurring of vision or impaired vision in 11.22% (n=11)
patients. None of the patients studied complained of Transient ischemic attack or
stroke or Carotid revascularisation (Figure 5).
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ardiovascular Symptoms at Presentation
The cardiac symptoms studied were angina, shortness of breath on
xertion, pedal edema, myocardial infarction, history of coronary
vascularisation, palpitations and arrhythmias. The most common cardiac
omplaints were shortness of breath and pedal edema. Almost 43.87% (n=43) of
e patients in the study complained of shortness of breath on exertion. And
lmost a same number of patients (n=43) complained of the pedal edema at the
me of presentation. 11 patients (11.22%) complained of palpitations at the time
f presentation (Figure 6).
Figure 5. Nervous System Complaints at Presentation
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Figure 6. Cardiovascular Symptoms at presentation
The renal symptoms were also assessed in patients who were studied. 2%
(n=2) of the patient studied had increased thirst and 1 patient (n=1) complained
of nocturia. None of the patients studied complained of hematuria or nocturia.
Only 1 patient (n=1) complained of Intermittent claudication pain in the
legs. None of the patients studied complained of the cold extremities and none of
the patients had a history of revascularisation.
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The patients enrolled in the study were examined for any signs of
secondary hypertension, including features of Cushing's syndrome, features of
neurofibromatosis, abdominal murmurs, precordial murmurs, radiofemoral delay
and large differences between upper limb and lower limb blood pressures. None
of the patients studied had any of the following signs which would have suggested
a secondary cause of hypertension rather than a primary cause.
Figure 7. Distribution of Systolic Blood pressure
Mean systolic blood pressure in the studied population was 155 mm of Hg
with a standard deviation of 11 mm of Hg (Figure 7). The Mean diastolic blood
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pressure in the studied population was 93.94 mm of Hg with a standard deviation
of 5.14 mm of Hg (Figure 8). The Mean heart Rate was around 87 beats per
minute with a standard deviation of 10 beats per minute. All the values were
normally distributed among the study individuals.
Figure 8. Distribution of Diastolic Blood pressure
The Mean height of the population studied was 162.49 cm with a standard
deviation of 9.5 cm. The mean weight of the studied population was 68.55 kgs
with a standard deviation of 12.385 kgs. The mean abdominal Circumference of
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the population was 89.20 cm with a standard deviation 11.65 cm. Body Mass
index on average was 25.93 Kg/m2 with a Standard Deviation of 5.20 Kg/m2. The
average Body surface area was 1.72 m2 with a standard deviation of 0.25m2. All
the values were distributed normally in the population (Table 7).
Table 7. Baseline Clinical parameters
Parameter Mean (SD)
Height (in cm) 162.49 (9.5)
Weight (in Kg) 68.55 (12.39)
Body Mass Index (in Kg/m2) 25.92 (5.20)
Abdominal Circumference (in cm) 89.20 (11.65)
Body Surface Area (in m2) 1.72 (0.26)
Clinical Signs Elicited on Examination of the patient
The patients were also examined clinically to elicit symptoms and signs
related to hypertension and its complications. The patients had been evaluated for
any motor weakness; fundus examination was done to look for hypertensive
retinopathy; the cardiovascular system examination was done to look for S3, S4,
any murmurs, pedal edema, and by basal crepitations and the carotid arteries
were auscultatated to look for any murmurs. All peripheral pulses were examined
to rule out any peripheral arterial disease.
Hypertensive retinopathy
Out of the 98 patients, 72 (73.46%) of them had a normal fundus
examination, 22 (22.44%) of them had hypertensive retinopathy grade 1 and 4
73
(4.08%) of them had hypertensive retinopathy grade 2. None of the patients
examined had grade 3 or grade 4 retinopathy (Figure 9).
Figure 9. Prevalence of Hypertensive retinopathy in Study Population.
Cardiovascular Signs at presentation
The evaluation of the cardiovascular signs at presentation showed that
pedal edema was a commonest sign which was elicitable in around 57 (58.16%)
of the patients studied. Two patients (2%) of the study population had an S4 on
auscultation and Three patients (3 %) had an Ejection systolic murmur at the
apex (however an echocardiogram done on the same patient did not show any
valvular lesions) (Figure 10).
0%
0%
4.08%
22.44%
73.46%
0 10 20 30 40 50 60 70 80
Grade 4
Grade 3
Grade 2
Grade 1
Normal
Hypertensive retinopathy at presentation
(n=98)
74
Figure 10. Cardiovascular Signs at presentation
Only one patient(1%) had asymmetry in the pulse volume felt in both feet.
And only one patient (1%) had an audible bruit in his right carotid artery.
Baseline Blood investigations
All the patients who were involved in the study underwent estimation of
baseline by chemical parameters and the parameters which indicated the
underlying organ damage. The blood tests which were done in the patients
include hemoglobin, fasting blood glucose, fasting lipid profile, serum sodium,
serum potassium, serum creatinine, serum HSCRP, serum uric acid. Patients also
underwent an electrocardiogram and an echocardiogram. The M-mode
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measurements of LV end diastolic diameter (LVEDD), posterior wall thickness in
diastole (PWDd), interventricular septum thickness in diastole (IVSd) and ejection
fraction were recorded the data entry sheet. The urine albumin creatinine ratio
was also estimated in the early-morning sample in the patients included in the
study.
The mean hemoglobin of the population studied was 13.39 gms% (SD 1.73
gms%). The mean blood glucose was below the diabetic range in the population
with the mean of 102.23mg/dl (SD 19.57 mg/dl). The Low-density lipoprotein was
116.04 mg/dl (SD 30.41 mg/dl). The serum sodium and potassium levels were
also measured and they were within normal limits in all the study population.
The mean creatinine level was 0.77mg/dl (SD 0.19 mg/dl). The hsCRP had
a lot of values which were outliers especially if it was elevated. Hence a median
and interquartile range was used to describe the data. The median hsCRP was
2.31 with an interquartile range of 0.89-5.2. The mean serum uric acid was 5.0
mg/dl with a standard deviation of 1.3 mg/dl (Table 8).
Table 8. Baseline Investigations
Investigation Mean (SD)
Hemoglobin (gms%) 13.39 (1.73)
Fasting Glucose (mg/dl) 102.23 (19.57)
Total Cholesterol (mg/dl) 180.85 (39.31)
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Low Density Lipoprotein (mg/dl) 116.04 (30.41)
High Density Lipoprotein (mg/dl) 41.99 (10.21)
Serum Sodium (mEq/l) 138.02 (2.60)
Serum Potassium (mEq/l) 4.17 (0.38)
Serum Creatinine (mg/dl) 0.77 (0.19)
Serum HsCRP (mg/l) 4.26 (4.91)
Median – 2.31
Interquartile Range – 0.89 -5.2
Serum Uric Acid (mg/dl) 5.0 (1.3)
Electrocardiographic Data
The 12 lead electrocardiogram was done in all patients were included in the
study. They electrocardiogram was recorded and stored in the hospital
information system and was analyzed to look for the various indices of detecting
LVH.
Electrocardiogram was evaluated for left ventricular hypertrophy with the
use of three criteria - The Sokolow Lyon criteria, the modified Sokolow Lyon
criteria and the Cornell voltage product criteria.
The results showed that the Sokolow Lyon criteria was positive in 9
patients (9.2%) of the study population. The modified Sokolow Lyon criteria was
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positive in 20 patients (20.4%) of the study population. The Cornell voltage
product criteria was positive in 7 patients (7.1%) of the study population.
Criteria Number Satisfied (Percentage)
Sokolow Lyon Criteria 9 (9.2%)
Modified Sokolow Lyon criteria 20 (20.4%)
Cornell voltage product criteria 7 (7.2%)
Echocardiographic criteria
Figure 11. Figure 11. Distribution of LV mass Index in Females
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All the patients were enrolled in the study were evaluated using an
echocardiogram. The M-mode observations and ejection fraction were recorded in
all the patients. The results of the following listed below.
The mean LV end diastolic diameter was 43mm (SD 5.6mm). The mean
posterior wall thickness in diastole was 10.69mm (SD 1.49mm). The mean
interventricular septum thickness in diastole was 12.15mm (SD 10.34mm). The
mean ejection fraction was 57.09% (SD 2.54%). The average relative wall
thickness was 0.49 (SD 0.10) (Table 9). The average LV mass index in males was
98.84 g/m2 (SD 24.61 g/m2)(Figure 12). The average LV mass index in females
was 92.46 g/m2 (SD 24.60 g/m2) (Figure 13).
Figure 12. Distribution of LV mass Index in Males
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Table 9. Echocardiographic Parameters
Echocardiographic parameter Mean (SD)
LV end diastolic diameter in diastole (mm) 43 (5.6).
Posterior wall thickness in diastole (mm) 10.69 (1.49).
Interventricular septum thickness in diastole (mm) 12.15 (10.34).
Ejection fraction (%) 57.09% (2.54%)
LV mass index – Male (in g/m2) 98.84 (24.61)
LV mass index – Female (in g/m2) 92.46 (24.60)
Relative wall thickness 0.49 (0.10)
Renal parameters
Renal parameters that were assessed to identify in organ damage was
microalbuminuria and estimated GFR, which was calculated by the abbreviated
MDRD formula.
The mean estimated GFR was 106.90 ml/min/1.73m2 with a standard
deviation of 27.81ml/min/1.73m2. The mean albumin creatinine ratio in the
studied population was 48.27 mg/g. However, this value was confounded by the
presence of a few outliers which were huge. Hence the median and the
interquartile range were calculated. The median albumin creatinine ratio was
14.35mg/g. The interquartile range was between 4.77mg/g to 49.30mg/g.
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Table 10. Predictors of Renal Damage
Parameter Mean (SD)
eGFR (abbreviated MDRD) 106.90 (27.81)
Urine Albumin Creatinine Ratio 48.27 (103.67)
Median – 14.35 mg/g
Interquartile Range – 4.77 – 49.3 mg/g
Prevalence of asymptomatic cardiac damage
The prevalence of asymptomatic cardiac damage was calculated with the
electrocardiographic and the echocardiographic criteria. If the patient had the
presence of the LV hypertrophy, either by an echocardiographic criteria or
electrocardiographic criteria, then they were classified as having asymptomatic
cardiac damage. The electrocardiographic criteria used where either of Sokolow
Lyon criteria, modified Sokolow Lyon criteria or the Cornell voltage product criteria
being positive. The echocardiographic criteria used for classifying LV hypertrophy
was the LV mass index.
The total prevalence of asymptomatic cardiac damage in the population
studied was 29.59% (n=29). All the patients who had left ventricular hypertrophy
by Electra cardiogram were found to have LV hypertrophy by LV mass index
criteria in echocardiography. Echocardiography proved to be a very sensitive tool
to pick up left ventricular hypertrophy (Table 11).
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Table 11. . Prevalence of Asymptomatic Cardiac Damage
ELECTROCARDIOGRAPHIC CRITERIA Prevalence % (Number of patients)
1. Sokolow Lyon Criteria 9.2% (9)
2. Modified Sokolow Lyon Criteria 20.4% (20)
3. Cornell Voltage Product Criteria 7.1% (7)
ECHOCARDIOGRAPHIC CRITERIA
1. LV mass Index 29.59% (29)
Prevalence of asymptomatic renal damage
The prevalence of asymptomatic renal damage was calculated by the
following criteria. If any patient had a urine albumin creatinine ratio ≥ 30mg/g in 
the early-morning spot urine sample or if any patient had an estimated GFR <
60ml/min/1.73m2. (Table 12)
The prevalence of asymptomatic renal damage in the studied population
was 31.9% (n=30).
Table 12. Prevalence of Asymptomatic Renal Damage
Criteria Prevalence % (number of patients)
eGFR <60 ml/min 0 % (0)
Albumin Creatinine Ratio ≥ 30mg/g 31.9 % (30)
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HsCRP and Risk Factors
Table 13. HsCRP tertiles and Risk Factors
HsCRP and Risk Factors
Parameter Tertile 1
Mean (SD)
Tertile 2
Mean (SD)
Tertile 3
Mean (SD)
P
Number of patients 33 33 32
Mean Systolic
Pressure (in mmHg)
154.64(11.6) 158.4(12) 152 (8) 0.059
Mean Diastolic
Pressure (in mm Hg)
92.71(4.6) 92.61(4.8) 92.8 (5.2) 0.007
Mean Heart rate (in
bpm)
86.33(11.6) 88.5(10.42) 86.2(8.1) 0.587
Body mass Index in
(Kg/m2)
23.6(5.2) 26.15(4.1) 28.06 (5.2) 0.002
Total Cholesterol (in
mg/dl)
183.2(45.5) 186.5(39.56) 178.75 (32.6) 0.901
Low Density
lipoprotein (mg/dl)
113.77(36.4) 115.79(26.5) 118.6 (27.85) 0.812
High Density
lipoprotein (mg/dl)
42.33(10.6) 42 (8) 41.63 (11.86) 0.962
Serum Creatinine (in
mg/dl)
0.80(0.19) 0.78 (0.15) 0.74(0.22) 0.459
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The HsCRP values in the studied population were divided into the three
tertiles and the risk factors for organ damage in Hypertension were studied in
them. The three tertiles were compared with each other to look for any
association with ANOVA. HsCRP was significantly related to the Diastolic blood
pressure (p= 0.007) and to Body Mass Index (p=0.002). None of the other
studied risk factors had any association with the levels of HsCRP. (Table 13)
HsCRP and Asymptomatic Organ Damage
Table 14. HsCRP tertiles and Asymptomatic organ Damage.
HsCRP Tertiles and Asymptomatic organ damage
Parameter Tertile 1
Mean (SD)
Tertile 2
Mean (SD)
Tertile 3
Mean (SD)
P
LV Mass Index (in
g/m2)
97.06 (24.2) 101.84 (28.4) 89.40 (19.5) 0.123
Albumin Creatinine
ratio (mg/g)
Median-10.2
Interquartile
range – 25.45
Median – 12.9
Interquartile
range – 42
Median – 26.65
Interquartile
range – 80.1
0.698
eGFR (in
ml/min/1.72 m2)
109.54(36.77) 104.99 (16.4) 106.15(27) 0.792
The analysis of the HsCRP tertiles for any association with asymptomatic
organ damage as defined by the LV mass Index, Albumin Creatinine Ratio and the
eGFR also didn't show any significance.
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Uric acid tertiles in Men and Risk Factors
Table 15. Uric Acid Tertiles in Men and Risk Factors.
Uric Acid in Men and Risk Factors
Parameter Tertile 1
Mean (SD)
Tertile 2
Mean (SD)
Tertile 3
Mean (SD)
P
Number of patients 19 20 18
Mean Systolic
Pressure (in mmHg)
159 (11) 152.8 (10.7) 156.61 (8.603) 0.184
Mean Diastolic
Pressure (in mm Hg)
93.16(6.5) 94.33 (4.1) 94.33 (4.2) 0.718
Mean Heart rate (in
bpm)
86(10.3) 86.2 (13.7) 90.39 (9.09) 0.420
Body mass Index in
(Kg/m2)
23.72 (3.7) 26.0 (4.4) 24.43(6.3) 0.351
Total Cholesterol (in
mg/dl)
170.4(46) 189.8(41) 173.83(37.26) 0.312
Low Density
lipoprotein (mg/dl)
109.8(30.8) 122.2(30) 116.22(24.39) 0.414
High Density
lipoprotein (mg/dl)
40.9(15.2) 42.75(8.6) 37.50(6.2) 0.324
Serum Creatinine (in
mg/dl)
0.86(0.15) 0.92(0.14) 0.84(0.16) 0.403
The Uric acid tertiles were studied separately in men and women as they
have different peaks in the normative distribution. The Uric acid levels were again
divided into three tertiles in men and women and they were analyzed separately.
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The Uric acid level was not significantly associated with any risk factors in
the amongst the male patients in the study. (Table 15)
Uric acid tertiles in Men and Asymptomatic Organ Damage
Table 16. Uric acid tertiles in men and Asymptomatic Organ Damage
Uric acid in Men and Asymptomatic organ damage
Parameter Tertile 1
Mean (SD)
Tertile 2
Mean (SD)
Tertile 3
Mean (SD)
P
LV Mass Index (in
g/m2)
101.31(19.9) 100 (26.4) 94.88(27.76) 0.711
Albumin Creatinine
ratio (mg/g)
Median – 21.2
Interquartile
range – 26.4
Median – 13.55
Interquartile
range – 50.18
Median – 12.1
Interquartile
range – 57.65
0.784
eGFR (in
ml/min/1.72 m2)
101.5(23.0) 95.34 (15.9) 110 (46) 0.324
The comparison of the uric acid tertiles with the asymptomatic organ
damage in men showed no significant association between the Uric acid levels and
the asymptomatic cardiac or renal damage. (Table 16)
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Uric acid tertiles in Women and Risk Factors
Table 17. Uric Acid tertiles in women and Risk Factors
Uric Acid in Women and Risk Factors
Parameter Tertile 1
Mean (SD)
Tertile 2
Mean (SD)
Tertile 3
Mean (SD)
P
Number of patients 15 13 13
Mean Systolic
Pressure (in mmHg)
155.8(14) 152.85 (11.11) 152(8.7) 0.653
Mean Diastolic
Pressure (in mm Hg)
93.6(5.2) 94.31 (6.1) 94 (5.05) 0.943
Mean Heart rate (in
bpm)
86.4(9.1) 90 (8.8) 83.08 (5.25) 0.104
Body mass Index in
(Kg/m2)
25.76(4.4) 27.52(5.7) 29.69(4.73) 0.129
Total Cholesterol (in
mg/dl)
183.8(41.2) 179.69 (35.8) 189.6(28.7) 0.780
Low Density
lipoprotein (mg/dl)
101.4(34.47) 119.8 (31.2) 128.31(28.5) 0.082
High Density
lipoprotein (mg/dl)
44(10.8) 45.38(9.1) 42.85(6.8) 0.782
Serum Creatinine (in
mg/dl)
0.60 (0.08) 0.63(0.11) 0.65(0.12) 0.490
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Serum uric acid levels in, the women were studied after dividing them into
three tertiles and they were analyzed to see if they co-relate with any of the risk
factors for organ damage. The ANOVA however, showed that there was no co-
relation with any of the risk factors associated with organ damage in the studied
intervals. (Table 17)
Uric acid in Women and Asymptomatic Organ Damage
Table 18. Uric Acid tertiles in Women and asymptomatic organ damage.
Uric acid in Women and Asymptomatic organ damage
Parameter Tertile 1
Mean (SD)
Tertile 2
Mean (SD)
Tertile 3
Mean (SD)
P
LV Mass Index (in
g/m2)
99.86(25.56) 87.76 (24.57) 88.61(23.29) 0.350
Albumin Creatinine
ratio (mg/g)
Median – 12.9
Interquartile
range – 53.4
Median – 16
Interquartile
range – 50.9
Median – 17.8
Interquartile
range – 53.9
0.616
eGFR (in
ml/min/1.72 m2)
117.8 (19.1) 112.9 (23.7) 108.85(22.6) 0.555
The Uric acid tertiles when analyzed in women didn't show any co-relation
with asymptomatic cardiac or renal damage.
The Uric acid and the HsCRP tertiles when compared with the
asymptomatic organ damage with ANOVA showed that there was no co-relation
with any asymptomatic organ damage in the study participants.
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Discussion
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Discussion
The discussion of the results will be done under the following major
subheadings. Firstly, the demographics and the baseline characteristics will be
discussed. Then we will discuss the primary objectives of the study. This will be
followed by discussion of the secondary objectives and finally the discussion of the
other parameters, which we found a significant in the study and the ones, which
were not.
Basic Demographics and baseline characteristics
Age
The patients in the study were chosen between age groups of 30 to 60
years. This is done primarily because we wanted to recruit patients with essential
hypertension and exclude patients who would have a secondary cause of
hypertension. We also chose this age group because the previous study by Viazzi
et al which studied the effects of uric acid on patients with systemic hypertension
had most of the population in the age group of 30 to 60 years. The minimum age
of recruitment in the study was 30 years and the oldest patient in the study was
61 years. This helped us to choose the patients who had most likely essential
hypertension and not hypertension due to secondary causes.
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Baseline Characteristics
The study population was divided into three major groups based on the
grade of hypertension for the basis of classification of the patients and study the
difference in the basal characteristics and also effects of organ damage the
different groups.
Sex
The number of males and females in the study were almost equally
distributed. Even after dividing the population into three groups based on
hypertensive grade the males slightly outnumbered the females in people with
grade 1 hypertension. However, in patients with grade II hypertension the males
outnumbered females by a ratio of 2:1. (Table 19)
Table 19. Baseline characteristics of the three groups of Hypertensives.
Parameter Hypertension
Grade I
Mean (SD)
Hypertension
Grade II
Mean (SD)
Hypertension
Grade III
Mean (SD)
Number 68 27 3
Age (years) 46.71(8.2) 47.63(8.9) 49(6.5)
Males (%) 54.4 70.4% 33%
Mean Systolic
Pressure (mm Hg)
149.81(5.7) 165.63(10.44) 179.33(3.055)
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Mean Diastolic
Pressure (mm Hg)
92.02(3.76) 97.89(5.00) 102(6.9)
Height (cm) 161.87(9.8) 164.37(9.0) 159(7.6)
Weight (Kg) 69.67(11.93) 65.81(13.71) 67.92(8.84)
Body Mass Index
(Kg/m2)
26.51(5.33) 24.37(4.81) 26.71(3.55)
Abdominal
Circumference
(cm)
101(11.93) 86.63(11.29) 91.67(5.51)
Body Mass Index and Abdominal Circumference
The body mass index in the grade I hypertensives was much higher
compared to the grade II hypertensives. This difference is, however unexplained.
This might be probably due to the fact that a lot of grade I hypertensives might
actually be people who had an underlying metabolic syndrome.
The rest of the clinical variables were comparable between the three
different groups of hypertensives.
Baseline Investigation Data
Table 20. Baseline investigations
Parameters Hypertension
Grade I
Mean (SD)
Hypertension
Grade II
Mean (SD)
Hypertension
Grade III
Mean (SD)
Fasting Blood Sugar
(mg%)
103.32(20.67) 98.81(17.51) 108.33(4.7)
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Total Cholesterol
(mg/dl)
183.38(39.32) 174.3(35.25) 182.33(79.28)
Low density
lipoprotein (mg/dl)
118.15(27.8) 116.89(29.87) 60.77(50.9)
High Density
Lipoprotein (mg/dl)
41.09(9.664) 44.33(11.74) 41.33(5.7)
Serum Sodium
(mEq/l)
138.04(2.6) 138.04(2.54) 137.33(1.15)
Serum Potassium
(mEq/l)
4.19(0.35) 4.1(0.46) 4.2(0.34)
Serum Creatinine
(mg/dl)
0.728(0.20) 0.78(0.16) 0.65(0.15)
HsCRP (mg/L) 4.96(5.33)
Median: 3.02
Interquartile
range: 6.35
2.83(3.55)
Median: 1.66
Interquartile
range: 2.11
1.55(1.37)
Uric Acid (mg%) 5.084(1.24) 4.88(1.46) 4.5(1.11)
Ejection Fraction
(%)
LV Mass Index
(g/m2)
Male
Female
93.94(19.9)
95.51 (17.56)
92.06 (22.62)
100.92(31.03)
101.84 (31.50)
98.75 (31.90)
104(55.97)
165 (0)
73.5 (26.16)
Relative Wall
Thickness
0.49(0.08) 0.499(0.14) 0.47(0.07)
Albumin-Creatinine
Ratio (mg/g)
46.19(73.56)
Median: 15
Interquartile
range: 46.05
55.67(161.19)
Median: 10.2
Interquartile
range: 43.3
28.9(27.35)
Median: 16.9
eGFR (MDRD)
ml/min
106(30.80) 108.08(20.02) 116(18.12)
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The Baseline investigation data for the different groups of hypertensives
and given in the above table (Table 20). From the table, we can see that the
Baseline investigations are pretty well matched among all the different groups of
hypertensives.
However, on a careful examination between the grade I and grade II
hypertensives, the grade I hypertensives are found to have a slightly
increased blood glucose, total cholesterol levels and significantly
increased HsCRP level. When we compare this data along with the fact that
these patients who belonged to the grade one hypertension also had an elevated
BMI compared to the grade II hypertensives, we come to a conclusion that this
might be due to increased prevalence of metabolic syndrome among the
group I hypertensives.
The HSCRP and the urine albumin creatinine ratio had quite a few outliers
which made the mean and standard deviation unreliable methods for comparison.
Hence the median and the interquartile range have been provided for the
comparison.
This table also brings out an important fact that the asymptomatic
end organ damage is not dependent on the grade of hypertension. There
was a slight increase in LV mass index in female patients in grade II
hypertension compared to females in the grade I hypertension group.
Except for this, there was no significant difference in the eGFR, relative wall
thickness and the urine albumin creatinine ratio which is evident from the table
among the three different groups.
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Primary objective
a. Prevalence of asymptomatic cardiac damage
The prevalence of asymptomatic cardiac damage in a study was 29.59%
with 29 of the 98 patients having an elevated LV mass index. This was the most
sensitive index to detect the LV hypertrophy in our study. The next most sensitive
marker in a study to detect LV hypertrophy was the modified Sokolow Lyon
criteria. It picked up 20.4% (n=20) of the patients with LV hypertrophy.
One of the earlier studies to look at the prevalence of LV mass index was
studied done in the Italian population by Viazzi et al. The study28 reported the
prevalence of asymptomatic cardiac damage in newly detected hypertensives to
be 45%.
In a recent study done in Kashmir published in June 2014, the prevalence
of asymptomatic cardiac damage is estimated by the LV mass index was found to
be 42% in newly detected hypertensives. This was in contrast to
electrocardiographic diagnosis of just 16% in the same population90.
The LV mass index serves as a very good indicator for predicting the LV
hypertrophy in newly detected patients with systemic hypertension.
In a study, the Cornell voltage product criteria had the least sensitivity in
the prediction of the LV hypertrophy. However, in a recent study done in Italy it
was found to be more sensitive to predict cardiovascular events and it was also
found to be more sensitive than the Sokolow Lyon index91. However, this might be
a difference due to the population in which the study was conducted.
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In one of the recent studies published in 2013, the investigators looked at
the correlation between LV mass and the Sokolow Lyon criteria in patients with
hypertension, aortic stenosis and hypertrophic cardiomyopathy. We postulated
that Sokolow Lyon criteria might not only predict structural changes (LV
hypertrophy) but also predict the functional changes. They found that Sokolow
Lyon index correlated with LV mass index (p<0.001) and with the global
longitudinal strain (p<0.001). They found that the correlation was stronger for the
global longitudinal strain in patients with hypertension. The Sokolow Lyon index
appears to be a very good indicator to predict both structural and functional left
ventricular statuses.
We find that the prevalence of LV hypertrophy in newly detected
hypertensives is alarming in almost all the studies which had looked at it. Hence,
it's imperative to diagnose it at the time of the patient being diagnosed with
hypertension. An echocardiogram at the time of diagnosis should be considered in
patients with hypertension, especially in those with other risk factors which
increased cardiovascular risk and in patients who are obese where the ECG criteria
might not be sensitive.
b. Prevalence of asymptomatic renal damage
The prevalence of asymptomatic renal damage in our study population was
around 31.9%. 30 out of the 90 participants in the study had increased urine
albumin creatinine ratio. However, none of the patients included in the study were
found to have an eGFR < 60ml/min/1.73 m2.
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Urine microalbuminuria in patients who do not have an active urinary
infection seem to be a very early marker of hypertension renal damage. And it is
at the state, when the renal function is not impaired, the treatment is most
effective. Most of the hypertensive societies now recommend routine screening at
the diagnosis of hypertension to look for urine microalbuminuria.
In a recent study done in Tamil Nadu, the prevalence of microalbuminuria
was studied in patients with essential hypertension. The study showed that 64%
of the study population had microalbuminuria. The probable reason for this high
incidence of urine microalbuminuria might be because the study population was
mostly found to having grade II hypertension and they were recruited from a
hospital37.
The study done by Viazzi et al. the prevalence of microalbuminuria was
12%. However, it is to be taken into account that the study was done in Italy.
The screening programs for detection of noncommunicable diseases in Italy are
much better than in a developing country like India.
In another study done in Karnataka, the prevalence of microalbuminuria
was 26% out of the 100 patients were studied. However, this study did not take
in new hypertensives alone. The study included both new and old hypertensives
on treatment. The study also showed there was a significant correlation between
uric acid levels and the left ventricular hypertrophy the population studied92.
The prevalence of microalbuminuria in some studies was related to
the stage of hypertension, however there is conflicting evidence. Not all studies
show this uniform relationship. The prevalence of microalbuminuria also varies
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with stage of hypertension and the population being studied. With the onset of
hypertension in a person is never being picked up early in a country like India due
to lack of good screening programs, it is very difficult to say whether a longer
duration of hypertension causes high prevalence urine microalbuminuria.
Microalbuminuria has been traditionally been associated with diabetes
mellitus while 24 hour urine protein or urine protein creatinine ratio was used to
detect proteinuria in non-diabetic conditions. However, in the recent days it has
been found that urine microalbuminuria or the albumin creatinine ratio is much
better marker as it detects early proteinuria which can be missed by urine protein
creatinine ratio. Hence a lot of guidelines now prefer measuring urine albumin
creatinine ratio or the urine microalbumin even in patients with non-diabetic
disease93.
Urine microalbumin or the albumin creatinine ratio is a very simple test to
detect early hypertensive injury to the kidney and should be done in all patients
diagnosed with hypertension as it is a very cost-effective and simple test. The
duration at which to repeat urine albumin creatinine ratio, if it was negative at the
time of diagnosis, is undefined. This requires further studies to come up with
recommendations.
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Secondary outcomes
a. HsCRP and asymptomatic organ damage
One of the secondary objectives was to evaluate serum HsCRP levels with
asymptomatic cardiac and renal damage. This was done by dividing the study
population into three tertiles based on the serum HsCRP levels.
The ANOVA showed that there was no relationship between asymptomatic
organ damage and HsCRP levels. However, there were a few very significant
associations.
HsCRP levels were significantly associated with the body mass
index , F(2,95)=6.625, P=0.002. The HsCRP levels were also significantly
related to the diastolic blood pressure, F(2,95)=5.280, P=0.007. The systolic
blood pressure also showed a trend towards significance with HsCRP Levels,
F(2,95)=2.920, P=0.059.
These values bring about a very curious question to be answered. All the
studies which have been done before have studied the levels of HsCRP and its
association with hypertension. The very fact that HsCRP is not associated with
asymptomatic organ damage, but is associated with body mass index and diastolic
blood pressure makes us think if it was confounded by some other factor.
The association between HsCRP and obesity is very well-known. HsCRP is
one of the markers of increased visceral fat. And it also plays an important role in
people with metabolic syndrome. Multiple studies have shown the association
between obesity and HsCRP.
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Study done on obese women showed low levels of adiponectin and it was
found that this was associated with an increase in inflammatory markers like
HsCRP and interleukin-6. The elevation of these inflammatory markers puts these
women in a higher cardiovascular risk94.
Another study was done in obese women have undergone bariatric surgery
(gastric banding) to see the effect on inflammatory markers. The study showed
that as the patients lost significant amounts of weight there was a significant
decrease in the HsCRP levels in the blood. The HsCRP pregastric banding was
1.33+/-1.21 mg/dl and it reduced to 0.40+/-0.61 mg/dl in post-gastric banding
period after the significant weight loss95.
Both these studies tell us that obesity is significantly related to HsCRP. The
studies in hypertension, which showed association of HsCRP to blood pressure
needs to be re-looked to see if they were confounded by the obesity in the study
subjects.
b. Uric acid levels and asymptomatic organ damage
Serum uric acid was analyzed individually for males and females and they
were also divided into three Tertiles. That tertiles of uric acid was compared with
markers of asymptomatic organ damage (LV mass index, urine albumin creatinine
ratio and eGFR) with ANOVA. There was no significant association between uric
acid and any of the markers of asymptomatic organ damage.
The results could be slightly biased as the number of patients in each
group was very less as the whole study group had to be divided into males and
100
females. The study was not sufficiently powered to detect any difference in the
asymptomatic organ damage due to elevated levels of uric acid.
A larger study is hence required to look for any statistically significant
results.
c. HsCRP and uric acid with Risk factors for
hypertension.
HSCRP and uric acid were studied to look for any association with the risk
factors for hypertension and asymptomatic organ damage. This was done with the
help of a bivariate analysis to look for any statistically significant correlation.
The table below shows the results of the Bivariate analysis.
Table 21. HsCRP and Risk Factors
Variables HsCRP
R P
Age 0.002 .981
Systolic Pressure -.118 .246
Diastolic Pressure -.74 .469
BMI .356 0.000
Abdominal Circumference .295 0.003
Mean Heart rate 0.25 .809
Total Cholesterol -0.58 .573
LDL 0.26 .803
HDL -0.85 .570
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The bivariate analysis showed the BMI and the abdominal
circumference correlated significantly with the HsCRP levels. (Table 21)
Table 22. Uric acid and risk Factors
Variable Males Females
R P r P
Age -.223 0.96 -0.39 0.811
Systolic Pressure -0.73 .591 -0.93 0.564
Diastolic Pressure 0.20 .881 0.145 0.366
Heart Rate 0.177 0.187 -0.258 0.103
Abdominal Circumference 0.065 0.631 0.262 0.097
Body Mass Index 0.121 0.369 0.368 0.018
Total Cholesterol 0.011 0.933 0.078 0.629
LDL 0.042 0.755 0.249 0.116
HDL -0.269 0.43 -0.150 0.349
Serum Creatinine 0.200 0.228 0.291 0.065
eGFR -0.038 0.778 -0.286 0.070
The bivariate analysis of uric acid was done separately for males and females. The
only significant correlation was between body mass index in females and serum
uric acid. This co-relation was not seen between the uric acid tertiles analyzed by
ANOVA. This might just be an association which a larger study might be able to
tell us better. This is, however an expected correlation which has been very well
documented before. (Table 22)
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d. Left ventricular geometries in the study population
There are four types of ventricular geometries defined in the patients with
systemic hypertension. They are normal LV geometry, concentric remodelling,
eccentric hypertrophy and concentric hypertrophy. The four types studied based
on the LV mass index and relative wall thickness.
In our study, we found a very significant number of patients with
concentric remodelling (57.7%, n=56) of the heart. There were four patients with
eccentric hypertrophy and 25 patients with concentric hypertrophy of the left
ventricle. Only 12.4% (n=12) had a normal LV geometry in the studied
population. (Table 21)
Table 23. Prevalence of Different Left Ventricular Geometries
LV Geometry
Normal 12.4% (12)
Concentric remodeling 57.7% (56)
Eccentric Hypertrophy 4.1% (4)
Concentric Hypertrophy 25.8% (25)
Concentric remodelling is considered as one of the adaptations of the heart
to increased cardiac overload. The prevalence of concentric remodelling in
patients with hypertension varies in various populations and in various studies.
Few studies have shown that concentric remodelling actually has an intermediate
risk for future cardiovascular events and it is also an independent predictor of
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systolic and diastolic dysfunction. However, more studies are needed to quantify
the risk of cardiovascular events due to concentric remodelling.
Such a high proportion of patients presenting with concentric remodelling
needs a study in India to see if the prevalence is the same or is it lower. We also
need long-term cohort studies to see if there are any adverse prognostic events
associated with concentric remodelling the Indian population.
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Concluding Remarks
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Conclusion
1. The prevalence of asymptomatic organ damage in newly detected
treatment naive hypertensives in our centre this very high. The prevalence
of asymptomatic renal damage was 31.9% (n=30) and the prevalence of
asymptomatic cardiac damage was 29.59%(n=29)
2. There was no association between the inflammatory markers, HsCRP and
uric acid with asymptomatic organ damage in patients with hypertension,
however this leads to be confirmed in a larger trial.
3. There was an association between HsCRP with body mass index and
abdominal circumference in the study.
4. There was a very high incidence of concentric remodelling in our population
which leads to be further clarified and the consequences have to be studied
by following up these patients.
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Clinical implications
1. Almost one third of the patients included in the study had asymptomatic
organ damage and this implies that all patients were newly diagnosed with
hypertension should be screened for asymptomatic cardiac and renal
damage.
2. It is better to screen high-risk patients and obese individuals who present
with hypertension for LV hypertrophy with echocardiogram as the
electrocardiogram can miss out patients with left ventricular hypertrophy.
3. All patients who are newly diagnosed with hypertension should have in
urine albumin creatinine ratio done to screen for asymptomatic renal
damage.
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Limitations
The sample size was small in the study as the recruitment was done in a
tertiary care centre and the number of patients presenting with isolated
hypertension was very small. Patients had multiple other comorbidities and hence
could not be included in the study.
We suggest repeating the study on a community basis in a cohort so that
the patients can be followed up in the inferences can be drawn upon on a
continuous basis over the years which will help us manage hypertension in a
much better way.
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Directions for future research
1. Need for a cohort study on hypertension in India is the need of the day as
all the data we have on hypertension is from the west.
2. The left ventricular geometry in Indian population needs to be studied in
more detail.
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